Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617SXK

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 4	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 5	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 6	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 7	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 8	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9	MAR 22	EMBASE is now updated on a daily basis
NEWS 10	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 12	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 13	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 14	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 15	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 16	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 17	MAY 11	KOREAPAT updates resume
NEWS 18	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 19	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 20	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 21	JUN 02	The first reclassification of IPC codes now complete in INPADOC

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:25:29 ON 14 JUN 2006

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                             ENTRY    SESSION
FULL ESTIMATED COST                                           0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:25:51 ON 14 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 JUN 2006  HIGHEST RN 887650-39-7
DICTIONARY FILE UPDATES:  13 JUN 2006  HIGHEST RN 887650-39-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s formoterol/cn
L1            1 FORMOTEROL/CN

=> d str cn rn

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN

Relative stereochemistry.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CN Formamide, N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, rel- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (R*,R*)-(±)-
OTHER NAMES:
CN (±)Formoterol
CN Eformoterol
CN Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (R*,R*)-
CN **Formoterol**
CN Oxis
RN 73573-87-2 REGISTRY

=> s fluticasone
L2 7 FLUTICASONE

=> s fluticasone/cn
L3 1 FLUTICASONE/CN

=> d L3 str cn rn

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CN Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxo-, S-(fluoromethyl) ester, (6α,11β,16α,17.alpha.)- (9CI) (CA INDEX NAME)
OTHER NAMES:

CN **Fluticasone**
RN 90566-53-3 REGISTRY

=> file caplus
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 19.40 | 19.61

FILE 'CAPLUS' ENTERED AT 14:27:38 ON 14 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Jun 2006 VOL 144 ISS 25
FILE LAST UPDATED: 13 Jun 2006 (20060613/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 73573-87-2
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L5 646 L4

=> s 90566-53-3/rn
391 90566-53-3
19 90566-53-3D
L6 379 90566-53-3/RN
(90566-53-3 (NOTL) 90566-53-3D)

=> s L5 and L6
L7 87 L5 AND L6

=> dup rem L7
PROCESSING COMPLETED FOR L7
L8 87 DUP REM L7 (0 DUPLICATES REMOVED)

=> s L8 and (AY<2002 or PY<2002 or PRY<2002)
L9 87 S L8
4142168 AY<2002
21819042 PY<2002

```
      3591199 PRY<2002
L10         41 L9 AND (AY<2002 OR PY<2002 OR PRY<2002)

=> d 1-41 ibib abs

L10  ANSWER 1 OF 41  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:95263  CAPLUS
DOCUMENT NUMBER:          140:151934
TITLE:                    Formulations of antiallergic agents with lactalbumin
                          hydrolyzate
INVENTOR(S):              Goerne, Martin
PATENT ASSIGNEE(S):       Kosmas K.-G., Germany
SOURCE:                   Ger. Offen., 10 pp.
                          CODEN: GWXXBX
DOCUMENT TYPE:            Patent
LANGUAGE:                 German
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     DE 10158036           A1    20040205    DE 2001-10158036        20011127 <--
PRIORITY APPLN. INFO.:                       DE 2001-10158036        20011127 <--
AB   The invention concerns pharmaceutical compns. that contain an allergy
     inhibitor and lactalbumin hydrolyzate; the lactalbumin hydrolyzate and the
     allergy inhibitor act syntergetically.  Lactalbumin hydrolyzates are
     prepared by enzymic digestion with papain, pancreatin and at least one
     bacterial protease followed by series of extns. and dryings with ethanol
     and isopropanol.  Thus a soft gel capsule contained (mg): prednisone 5;
     lactalbumin hydrolyzate fraction 10; soybean oil 440; soy lecithin 50;
     silica 5.

L10  ANSWER 2 OF 41  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2003:777110  CAPLUS
DOCUMENT NUMBER:          139:286353
TITLE:                    Methods and compositions using trefoil peptides for
                          treating lesions of the respiratory epithelium
INVENTOR(S):              Podolsky, Daniel K.
PATENT ASSIGNEE(S):       The Gi Company, Inc., USA
SOURCE:                   U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S.
                          Ser. No. 362,310.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   16
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     US 2003185838         A1    20031002    US 2003-431805          20030508 <--
     US 6221840            B1    20010424    US 1996-631469          19960412 <--
     WO 9738712            A1    19971023    WO 1997-US6004          19970411 <--
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
             RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN
         RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,
             ML, MR, NE, SN, TD, TG
     US 2003114384         A1    20030619    US 2002-305747          20021127 <--
     CA 2480372            AA    20031009    CA 2003-2480372         20030326
     AU 2003224773         A1    20031013    AU 2003-224773          20030326
     EP 1494530            A2    20050112    EP 2003-721462          20030326
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
```

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005527547	T2	20050915	JP 2003-579739	20030326	
WO 2004039961	A2	20040513	WO 2003-US34796	20031031	

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003286844	A1	20040525	AU 2003-286844	20031031	
EP 1581623	A2	20051005	EP 2003-778060	20031031	

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:	US 1996-631469	W	19960412 <--
	WO 1997-US6004	W	19970411 <--
	US 2001-333836P	P	20011128 <--
	US 2002-422708P	P	20021031
	US 2002-305747	A2	20021127
	US 2003-362310	A2	20030219
	US 1991-655965	B2	19910214 <--
	US 1992-837192	B2	19920213 <--
	US 1993-37741	B2	19930325 <--
	US 1994-191352	B2	19940202 <--
	US 2002-367574P	P	20020326
	US 2003-397953	A	20030326
	WO 2003-US9195	W	20030326
	US 2003-431805	A	20030508
	US 2003-434607	A	20030509
	US 2003-434636	A	20030509
	US 2003-434752	A	20030509
	US 2003-435406	A	20030509
	WO 2003-US34796	W	20031031

AB This invention features methods of treating lesions of the airway epithelium by local or systemic administration of (intestinal) trefoil peptides. The intestinal trefoil peptide can be administered either alone or in combination with one or more therapeutic agents.

L10 ANSWER 3 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2003:434320 CAPLUS
DOCUMENT NUMBER:	139:17578
TITLE:	Methods and compositions for treating lesions of the respiratory epithelium
INVENTOR(S):	Podolsky, Daniel K.
PATENT ASSIGNEE(S):	The General Hospital Corporation, USA
SOURCE:	PCT Int. Appl., 46 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	16

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045332	A2	20030605	WO 2002-US38258	20021127 <--
WO 2003045332	A3	20030724		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,

TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2468344	AA	20030605	CA 2002-2468344		20021127 <--
AU 2002351181	A1	20030610	AU 2002-351181		20021127 <--
EP 1461076	A2	20040929	EP 2002-786828		20021127 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
CN 1617739	A	20050518	CN 2002-827590		20021127 <--
JP 2005532988	T2	20051104	JP 2003-546837		20021127 <--
PRIORITY APPLN. INFO.:			US 2001-333836P	P	20011128 <--
			WO 2002-US38258	W	20021127

AB The present invention features methods and compns. for the treatment of lesions of the airway epithelium in mammals, by administering to the mammal therapeutically effective amts. of trefoil peptides, or a biol. active fragments thereof. Treatment of lesions according to the invention can speed healing, reduce pain, delay or prevent the occurrence of the lesion, and inhibit expansion, secondary infection, or other complications of the lesion. Lesions of the airway epithelium may result from any cause, including for example, an allergic reaction, asthma, an infection, an inhaled chemical or particulate exposure, a thermal lesion, smoke inhalation, drug-induced lung damage, trauma (caused, for example, by surgery or intubation), a microbial infection (e.g., bacterial, viral, or fungal), chronic obstructive pulmonary disease, antineoplastic therapy, cystic fibrosis, cardiovascular compromise such as congestive heart failure, or hyperbaric oxygen therapy. In all foregoing aspects of the invention, the mammal is preferably a human and the trefoil peptide is human intestinal trefoil factor (ITF), spasmolytic peptide (SP), pS2, or biol. active fragments thereof. Such fragments include for example, ITF15-73, ITF21-73, ITF1-72, ITF15-72, or ITF21-72. In the methods and compns. of this invention, a second therapeutic agent can be included. Such agents include antiinflammatory agents such as glucocorticoids (beclomethasone, flunisolide, budesonide, triamcinolone, prednisolone, dexamethasone, or fluticasone) or nonsteroidal antiinflammatory agents (e.g., ibuprofen, tacrolimus, cromolyn, nedocromil, rofecoxib, or celecoxib); antimicrobial agents (e.g., amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, streptomycin, or tobramycin); antihistamines (e.g., diphenhydramine, fexofenadine, cetirizine, or loratadine); cholinergic receptor antagonists (e.g., ipratropium bromide or tiotropium); neurokinin receptor antagonists; leukotriene receptor antagonists; decongestants; phosphodiesterase inhibitors; or β-adrenergic receptor antagonists (albuterol, bitolterol, epinephrine, fenoterol, formoterol, isoetharine, isoproterenol, metaproterenol, pirbuterol, procaterol, rac-epinephrine, salmeterol, or terbutaline). The second therapeutic agent may be administered within (either before or after) 14 days, 7 days, 1 day, 12 h, 1 h, or simultaneously with the trefoil peptide.

L10 ANSWER 4 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2003:376127 CAPLUS
DOCUMENT NUMBER:	138:390904
TITLE:	Water stabilized medicinal aerosol formulation
INVENTOR(S):	Adjei, Akwete; Cutie, Anthony J.
PATENT ASSIGNEE(S):	USA
SOURCE:	U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U. S. Ser. No. 619,183, abandoned. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	3
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003091512	A1	20030515	US 2002-234825	20020903 <--
US 6261539	B1	20010717	US 1998-209228	19981210 <--
CA 2497171	AA	20040318	CA 2003-2497171	20030903
WO 2004022035	A1	20040318	WO 2003-US27245	20030903
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003272251	A1	20040329	AU 2003-272251	20030903
EP 1569617	A1	20050907	EP 2003-754425	20030903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006502160	T2	20060119	JP 2004-534386	20030903
PRIORITY APPLN. INFO.:			US 1998-209228	A2 19981210 <--
			US 2000-619183	B2 20000719 <--
			US 2002-234825	A 20020903
			WO 2003-US27245	W 20030903

AB This invention relates to a medicinal aerosol suspension formulation and more particularly, to a medicinal aerosol formulation containing a particulate drug or a combination of at least two particulate drugs, a propellant and a stabilizing agent comprising a water addition

L10 ANSWER 5 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:355834 CAPLUS
DOCUMENT NUMBER: 138:362665
TITLE: Immunostimulatory nucleic acids for the treatment of asthma and allergy
INVENTOR(S): Bratzler, Robert L.; Petersen, Deanna M.; Fouron, Yves
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 221 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003087848	A1	20030508	US 2001-776479	20010202 <--
US 2004067902	A9	20040408		
US 2004235774	A1	20041125	US 2004-831778	20040423 <--
PRIORITY APPLN. INFO.:			US 2000-179991P	P 20000203 <--
			US 2001-776479	A1 20010202 <--

OTHER SOURCE(S): MARPAT 138:362665
AB The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an asthma/allergy medicament for the treatment or prevention of asthma and allergy in subjects. The combination of drugs are administered in synergistic amts. or in various dosages or at various time schedules. The invention also relates to kits and compns. concerning the combination of drugs.

L10 ANSWER 6 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:257320 CAPLUS
DOCUMENT NUMBER: 138:260488
TITLE: Method for the production of sterile liquid preparations for inhalation

INVENTOR(S): Keller, Manfred; Lintz, Frank
PATENT ASSIGNEE(S): Pari Gmbh, Germany
SOURCE: Ger. Offen., 14 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10145361	A1	20030403	DE 2001-10145361	20010914 <--
EP 1417958	A1	20040512	EP 2002-25006	20021108 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CA 2475577	AA	20040521	CA 2003-2475577	20031028
WO 2004041253	A1	20040521	WO 2003-EP11949	20031028
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003279326	A1	20040607	AU 2003-279326	20031028
EP 1558217	A1	20050803	EP 2003-772269	20031028
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006057073	A1	20060316	US 2004-517910	20041208

PRIORITY APPLN. INFO.:
DE 2001-10145361 A 20010914 <--
EP 2002-25006 A 20021108
WO 2003-EP11949 W 20031028

AB The invention concerns the production of sterile aqueous inhalation aerosols containing slightly soluble drugs by (a) preparing an aqueous suspension containing drug particles larger than 1 μm and a dissolved surfactant; (b) reduction of the particle size by high pressure homogenization or collision jet grinding to obtain particles less than 1 μm; (c) heat treatment of the suspension for sterilization, the final average particle size is less than 2 μm. The inhalants are formulated for pulmonary and nasal use. Suspensions can be nebulized by aerosol nozzles, ultrasound, vibrating membranes with defined pore sizes or electrohydrodynamically.

L10 ANSWER 7 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:44146 CAPLUS
DOCUMENT NUMBER: 138:73178
TITLE: Preparation and pharmaceutical combinations of [(hetero)arylalkyl]piperidinyl amine, amide, or carbamate CCR3 antagonists for treatment of asthma, allergic disease, or inflammation
INVENTOR(S): Bahl, Ash; Perry, Matthew; Springthorpe, Brian
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: Brit. UK Pat. Appl., 91 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

GB 2373186 A1 20020918 GB 2001-4534 20010223 <--
PRIORITY APPLN. INFO.: GB 2001-4534 20010223 <--
OTHER SOURCE(S): MARPAT 138:73178
GI



I



II

AB Title compds. I [wherein Z = CR4R5, CO, or CR4R5Z1; Z1 = alkylene, alkenylene, or CONH; R1 = (un)substituted alkyl, alkenyl, (hetero)cycloalkyl, or (hetero)aryl; Q = O, S, NR9, CO, CONR9, NR9CO, or CH=CH; m = 0-1; n = 0-6 with the proviso that when n = 0; then m = 0; R2 and R3 = independently H or alkyl; or CR2R3 = (alkyl)cycloalkyl; T = NR10, CONR10, NR11CONR10, or CONR10R11; X1-X4 = independently CH2CHR12 or CO; R4 and R5 = independently H or alkyl; R6 = (un)substituted (hetero)aryl; R9-R11 = independently H, alkyl, haloalkyl, hydroxyalkyl, cycloalkyl(alkyl), or phenylalkyl; R12 = independently (cyclo)alkyl or CO; or R12 groups of X1 and X3 or X4, or X2 and X3 or X4 join to form CH2CH2, CH2CH2CH2, CH2OCH2, or CH2SCH2; or pharmaceutically acceptable salts or solvates thereof] were prepared as cysteine-cysteine chemokine receptor 3 (CCR3) antagonists for use in pharmaceutical combinations with a histamine antagonist, steroid, leukotriene modulator, human cytokine, β-agonist, phosphodiesterase inhibitor, or antibody (no data). For example, 1-(3,4-dichlorobenzyl)-4-piperidinamine•2CF3CO2H was condensed with 2-(4-fluorophenyl)acetic acid to give N-[1-(3,4-dichlorobenzyl)-4-piperidinyl]-2-(4-fluorophenyl)acetamide (II). I are useful in combination therapy for the treatment of asthma, rhinitis, and other allergic or inflammatory conditions (no data).

L10 ANSWER 8 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:5762 CAPLUS
DOCUMENT NUMBER: 138:78452
TITLE: Pharmaceutical compositions containing anticholinergic agents, corticosteroids and betamimetic agents
INVENTOR(S): Meade, Christopher John Montague; Pieper, Michael P.; Pairet, Michel
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000241	A2	20030103	WO 2002-EP5896	20020529 <--
WO 2003000241	A3	20031211		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10130371	A1	20030102	DE 2001-10130371	20010623 <--
CA 2455167	AA	20030103	CA 2002-2455167	20020529 <--
EP 1408967	A2	20040421	EP 2002-745329	20020529 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005502608	T2	20050127	JP 2003-506888	20020529 <--
US 2003018019	A1	20030123	US 2002-173194	20020617 <--
US 2006057074	A1	20060316	US 2005-267354	20051104 <--
PRIORITY APPLN. INFO.:			DE 2001-10130371 A	20010623 <--
			US 2001-304148P P	20010710 <--
			WO 2002-EP5896 W	20020529
			US 2002-173194 A1	20020617

AB The invention relates to novel pharmaceutical compns. based on anitcholinergic agents, corticosteroids and betamimetic agents, to methods for their production and to their use for treating respiratory tract diseases. Thus an inhalation powder was prepared that contained (μg) per capsule: tiotropium bromide monohydrate 22.6; budesonide 200; salmeterol x 0.5 H2SO4 55.9; lactose 4721.6.

L10 ANSWER 9 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:813911 CAPLUS
DOCUMENT NUMBER: 137:316082
TITLE: Formoterol/steroid bronchodilating compositions and methods of use thereof
INVENTOR(S): Banerjee, Partha S.; Chaudry, Imitiaz A.
PATENT ASSIGNEE(S): Dey LP, USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083113	A2	20021024	WO 2002-US6252	20020301 <--
WO 2002083113	A3	20030320		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003055026	A1	20030320	US 2001-887496	20010622 <--
CA 2444535	AA	20021024	CA 2002-2444535	20020301 <--
EP 1385494	A2	20040204	EP 2002-719098	20020301 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005512944	T2	20050512	JP 2002-580917	20020301 <--
US 2002183293	A1	20021205	US 2002-145978	20020513 <--
PRIORITY APPLN. INFO.:			US 2001-284607P P	20010417 <--

	US 2001-887496	A1 20010622 <--
	WO 2002-US6252	W 20020301

AB Bronchodilating compns. intended for administration as a nebulized aerosol are provided. In certain embodiments, the compns. contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compns. provided herein are also provided. For example, a solution was prepared containing Formoterol fumarate dihydrate 85 μg/mL, budesonide 125 μg/mL, vitamin E TPGS 10 μg/mL, Polyethylene glycol 10 μg/mL, citrate buffer 50mM, sodium chloride 7.5 mg/mL, and water as needed.

L10 ANSWER 10 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:777694 CAPLUS
DOCUMENT NUMBER: 137:284361
TITLE: Drug delivery aerosols containing hydrofluoroalkanes and solid excipients
INVENTOR(S): Mueller-Walz, Rudi; Niederlaender, Carsten
PATENT ASSIGNEE(S): Jago Research A.-G., Switz.
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002078671	A1	20021010	WO 2002-CH145	20020311 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2442415	AA	20021010	CA 2002-2442415	20020311 <--
EP 1372608	A1	20040102	EP 2002-701145	20020311 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1499958	A	20040526	CN 2002-807382	20020311 <--
NZ 528640	A	20040625	NZ 2002-528640	20020311 <--
JP 2004525148	T2	20040819	JP 2002-576937	20020311 <--
ZA 2003007161	A	20041123	ZA 2003-7161	20030912 <--
NO 2003004323	A	20030926	NO 2003-4323	20030926 <--
US 2004101483	A1	20040527	US 2003-473874	20030930 <--

PRIORITY APPLN. INFO.:	CH 2001-601	A 20010330 <--
	CH 2001-1527	A 20010820 <--
	WO 2002-CH145	W 20020311

OTHER SOURCE(S): MARPAT 137:284361

AB The invention concerns drug delivery systems in form of aerosols that contain the active substance, the palmitates and stearates of calcium, magnesium and zinc as solid excipients, and hydrofluoroalkanes. Thus 24.96 g micronized budesonide and 3.12 g magnesium stearate were weighed in to a pressure vessel and filled with 7.8 kg HFA 134a. After homogenization the suspension was filled into aluminum inhalers.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:671829 CAPLUS
DOCUMENT NUMBER: 137:206550

TITLE: Inhalatory compositions of formoterol
INVENTOR(S): Gagnoni, Alessandro; Meoli, Andrea; Vanossi, Sereno
PATENT ASSIGNEE(S): Chemo Healthcare S.A., Switz.
SOURCE: Eur. Pat. Appl., 7 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1236467	A1	20020904	EP 2002-4635	20020228 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2374257	AA	20020902	CA 2002-2374257	20020301 <--
US 2002155068	A1	20021024	US 2002-86868	20020304 <--
✓ US 6719994	B2	20040413		

PRIORITY APPLN. INFO.: IT 2001-MI428 A 20010302 <--

AB Inhalatory pharmaceutical compns. containing formoterol as active ingredient, comprises a vial containing a sterile liquid vehicle suitable for inhalation, a reservoir chamber cap containing a powder mixture consisting of Formoterol or a related salt in micronized form and one or more excipients, soluble in the vehicle and suitable for respiratory use. The composition comprises a further active ingredient, i.e., budesonide, fluticasone, flunisolide, mometasone or ipratropium bromide.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 12 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:591707 CAPLUS
DOCUMENT NUMBER: 137:140509
TITLE: Preparation of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isozymes
INVENTOR(S): Chambers, Robert J.; Magee, Thomas V.; Marfat, Anthony
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 180 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1229034	A1	20020807	EP 2002-250202	20020111 <--
EP 1229034	B1	20050413		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 293109	E	20050415	AT 2002-250202	20020111 <--
ES 2239203	T3	20050916	ES 2002-2250202	20020111 <--
CA 2369462	AA	20020731	CA 2002-2369462	20020129 <--
US 2002111495	A1	20020815	US 2002-62811	20020131 <--
BR 2002000250	A	20021008	BR 2002-250	20020131 <--
US 2004171798	A1	20040902	US 2004-781062	20040217 <--

PRIORITY APPLN. INFO.: US 2001-265240P P 20010131 <--
US 1997-43403P P 19970404 <--
US 1998-105120P P 19981021 <--
US 2002-62811 B1 20020131

OTHER SOURCE(S): MARPAT 137:140509
GI



I

AB Title compds. [I; p, q = 0, 1; m = 0-2; n = 1, 2; A = CO2R7, CONR9CO2R7, CONR7R9, OP(O)(OH)2, SO3H, acylsulfonamido, etc.; W = O, S, SO, SO2, NR3; Y = N, NO, CR11; R1, R2 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, etc.; R3 = H, alkyl, Ph, PhCH2, etc.; R4-R6 = H, F, Cl, alkynyl, cyano, NO2, etc.; R7 = H, (substituted) alkyl, alkenyl, alkynyl; R9 = H, alkyl, cycloalkyl, Ph, PhCH2, pyridyl, etc.; R11 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, fluoroalkoxy, etc.; Ra, Rb = H, F, CF3, alkyl, (substituted) cycloalkyl, Ph, PhCH2; B1, B2 = 3-7 membered (hetero)cyclyl, 7-12 membered poly(hetero)cyclyl; pairs of variables may form rings; with provisos], were prepared (no data). Thus, Me 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionate was suspended in Me3COH. Aqueous NaOH was added to the suspension, and the reaction mixture was refluxed 1 h to give 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionic acid.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 13 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:556104 CAPLUS
DOCUMENT NUMBER: 137:109489
TITLE: Compositions comprising a polypeptide and an active agent
INVENTOR(S): Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randal J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 34 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 19
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002099013	A1	20020725	US 2001-933708		20010822 <--
US 2004087483	A1	20040506	US 2002-136433		20020502 <--
US 2006014697	A1	20060119	US 2005-89056		20050325 <--
PRIORITY APPLN. INFO.:			US 2000-247556P	P	20001114 <--
			US 2000-247558P	P	20001114 <--
			US 2000-247559P	P	20001114 <--
			US 2000-247560P	P	20001114 <--
			US 2000-247561P	P	20001114 <--
			US 2000-247594P	P	20001114 <--
			US 2000-247595P	P	20001114 <--
			US 2000-247606P	P	20001114 <--
			US 2000-247607P	P	20001114 <--
			US 2000-247608P	P	20001114 <--
			US 2000-247609P	P	20001114 <--
			US 2000-247610P	P	20001114 <--
			US 2000-247611P	P	20001114 <--
			US 2000-247612P	P	20001114 <--
			US 2000-247620P	P	20001114 <--
			US 2000-247621P	P	20001114 <--
			US 2000-247634P	P	20001114 <--

US 2000-247635P	P	20001114	<--
US 2000-247698P	P	20001114	<--
US 2000-247699P	P	20001114	<--
US 2000-247700P	P	20001114	<--
US 2000-247701P	P	20001114	<--
US 2000-247702P	P	20001114	<--
US 2000-247797P	P	20001114	<--
US 2000-247798P	P	20001114	<--
US 2000-247799P	P	20001114	<--
US 2000-247800P	P	20001114	<--
US 2000-247801P	P	20001114	<--
US 2000-247802P	P	20001114	<--
US 2000-247803P	P	20001114	<--
US 2000-247804P	P	20001114	<--
US 2000-247805P	P	20001114	<--
US 2000-247807P	P	20001114	<--
US 2000-247832P	P	20001114	<--
US 2000-247833P	P	20001114	<--
US 2000-247926P	P	20001114	<--
US 2000-247927P	P	20001114	<--
US 2000-247928P	P	20001114	<--
US 2000-247929P	P	20001114	<--
US 2000-247930P	P	20001114	<--
US 2000-642820	A2	20000822	<--
US 2000-248607P	P	20001116	<--
US 2001-933708	A2	20010822	<--
US 2002-358368P	P	20020222	
US 2002-358381P	P	20020222	
US 2002-362082P	P	20020307	
US 2002-366258P	P	20020322	
US 2002-156527	A2	20020529	
WO 2003-US5525	A2	20030224	
US 2003-507012P	P	20030930	
US 2004-567800P	P	20040505	
US 2004-567802P	P	20040505	
US 2004-568011P	P	20040505	
US 2004-923088	A2	20040823	
US 2004-923257	A2	20040823	
US 2004-953110	A2	20040930	
US 2004-953111	A2	20040930	
US 2004-953116	A2	20040930	
US 2004-953119	A2	20040930	
US 2004-955006	A2	20040930	
WO 2004-US32131	A2	20040930	

AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the composition to the patient. The peptide is a homopolymer of a naturally occurring amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)n-cephalexin was prepared from Glu(OBut)NCA and cephalexin hydrochloride.

L10 ANSWER 14 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:488054 CAPLUS
DOCUMENT NUMBER: 137:52413

TITLE: Spray dried powders for pulmonary or nasal administration

INVENTOR(S): Woolfe, Austen John; Zing, Xian Ming; Langford, Alan
PATENT ASSIGNEE(S): Norton Healthcare Ltd., USA

SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 643,145, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002081266	A1	20020627	US 2001-930109		20010814 <--
PRIORITY APPLN. INFO.:			US 1999-150095P	P	19990820 <--
			US 2000-643145	B2	20000821 <--

AB A formulation for pulmonary or nasal administration comprises a mixture of particles of 2 or more drugs or excipients produced by spray drying and suitable for administration without further processing of the particles. Spherical particles 1-5 μ in size and formed directly by spray-drying with salbutamol sulfate 120 parts and ipatropium bromide 20 parts by weight were prepared The larger proportion of salbutamol acted as an agent to cover the ipatropium bromide and so prevent moisture uptake by the ipatropium bromide. The increased weight of the particle compared to the ipatropium alone gave better content uniformity of the lower dose drug. The particles were either suspended in a mixture of P134a and/or P227 with a cosolvent (EtOH) or a surfactant as appropriate in a metered dose aerosol inhaler, or were mixed with lactose as a flow aid in a metered dose dry powder inhaler, or used as received from the spray dryer in a capsule for insufflation.

L10 ANSWER 15 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:487374 CAPLUS
DOCUMENT NUMBER: 137:52399
TITLE: Pharmaceutical aerosol formulations containing alkyl polyglycoside
INVENTOR(S): Buckton, Graham; Columbano, Angela; Grosvenor, Martin; Wikeley, Philip
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002049616	A1	20020627	WO 2001-SE2853		20011219 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002016576	A5	20020701	AU 2002-16576		20011219 <--
EP 1345591	A1	20030924	EP 2001-271213		20011219 <--
EP 1345591	B1	20050302			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004516261	T2	20040603	JP 2002-550958		20011219 <--
AT 289803	E	20050315	AT 2001-271213		20011219 <--
US 2004082520	A1	20040429	US 2003-451162		20031125 <--
PRIORITY APPLN. INFO.:			SE 2000-4750	A	20001219 <--
			WO 2001-SE2853	W	20011219 <--

OTHER SOURCE(S): MARPAT 137:52399

AB The invention relates to a pharmaceutical aerosol formulation comprising a surfactant that is an alkyl polyglycoside (the average degree of polymerization of

1-4) for the administration of a drug for inhalation. Propellant HFA-134a was was dispensed chilled (at -55°) into a 400-mL can. A valve was then crimped onto the can and the propellant allowed to return to ambient temperature Beclomethasone dipropionate was weighed into a 30-mL glass vial and 20 mL of surfactant (alkyl polyglycoside at 0.8 g/L) solution in water. The resultant suspension was incubated at 25° for 3 h hours, to allow adsorption of the surfactant to the surface of the drug, and to give a drug-surfactant ratio of 10 mg surfactant/g drug. The suspension was centrifuged and the particles of drug-surfactant were separated from the supernatant and dried in an oven at 50° for 24 h. This was mixed with the propellant, and the final composition contained beclomethasone dipropionate and glycoside 0.2% and HFA-134a to 100%.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 16 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:449474 CAPLUS
DOCUMENT NUMBER: 137:11011
TITLE: Particulate inhalation carriers
INVENTOR(S): Buckton, Graham; Al-Hadithi, Dima; Brocchini, Stephen
PATENT ASSIGNEE(S): School of Pharmacy, University of London, UK
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002045682	A1	20020613	WO 2001-GB5436		20011210 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002022145	A5	20020618	AU 2002-22145		20011210 <--
EP 1339388	A1	20030903	EP 2001-999355		20011210 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004517834	T2	20040617	JP 2002-547468		20011210 <--
US 2004062719	A1	20040401	US 2003-433435		20031020 <--
PRIORITY APPLN. INFO.:			GB 2000-30074	A	20001208 <--
			WO 2001-GB5436	W	20011210 <--

AB The present invention provides a particulate substrate suitable for carrying a drug for delivery, comprising a substantially crystalline core and a surface coating, wherein the particulate substrate has a proportion of amorphous character of 2% or greater by weight of particulate substrate, and a process for the production of carrier particles comprising the steps of: (a) mixing crystalline particles having an average diameter greater than 10 μm with at least partially amorphous particles having average diams. less than 10 μm; (b) exposing the mixture to conditions capable of inducing crystallization of the amorphous particles for a predetd. period in order that partial crystallization takes place. The core material is selected from saccharides, most preferably lactose and the surface of the substrate is formed from the same material as the core. The drug is selected from steroids, hormones,

therapeutic proteins and peptides, β-2 agonists, bronchodilators, corticosteroids and antihistamines.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 17 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:332011 CAPLUS
DOCUMENT NUMBER: 136:355482
TITLE: Compositions comprising a polypeptide and an active agent
INVENTOR(S): Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randall J.
PATENT ASSIGNEE(S): New River Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 19
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 2002034237	A1	20020502	WO 2001-US26142		20010822	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
US 6716452	B1	20040406	US 2000-642820		20000822	<--
CA 2420590	AA	20020502	CA 2001-2420590		20010822	<--
AU 2001086599	A5	20020506	AU 2001-86599		20010822	<--
EP 1311242	A1	20030521	EP 2001-966056		20010822	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
JP 2004523480	T2	20040805	JP 2002-537291		20010822	<--
US 2004127397	A1	20040701	US 2003-727565		20031205	<--
PRIORITY APPLN. INFO.:			US 2000-642820	A	20000822	<--
			US 2000-247613P	P	20001114	<--
			US 2000-247614P	P	20001114	<--
			US 2000-247615P	P	20001114	<--
			US 2000-247616P	P	20001114	<--
			US 2000-247617P	P	20001114	<--
			US 2000-247622P	P	20001114	<--
			US 2000-247630P	P	20001114	<--
			US 2000-247631P	P	20001114	<--
			US 2000-247632P	P	20001114	<--
			US 2000-247633P	P	20001114	<--
			US 2000-247556P	P	20001114	<--
			US 2000-247558P	P	20001114	<--
			US 2000-247559P	P	20001114	<--
			US 2000-247560P	P	20001114	<--
			US 2000-247561P	P	20001114	<--
			US 2000-247594P	P	20001114	<--
			US 2000-247595P	P	20001114	<--
			US 2000-247606P	P	20001114	<--
			US 2000-247607P	P	20001114	<--
			US 2000-247608P	P	20001114	<--
			US 2000-247609P	P	20001114	<--
			US 2000-247610P	P	20001114	<--
			US 2000-247611P	P	20001114	<--

US 2000-247612P	P	20001114	<--
US 2000-247620P	P	20001114	<--
US 2000-247621P	P	20001114	<--
US 2000-247634P	P	20001114	<--
US 2000-247635P	P	20001114	<--
US 2000-247698P	P	20001114	<--
US 2000-247699P	P	20001114	<--
US 2000-247701P	P	20001114	<--
US 2000-247702P	P	20001114	<--
US 2000-247797P	P	20001114	<--
US 2000-247798P	P	20001114	<--
US 2000-247799P	P	20001114	<--
US 2000-247800P	P	20001114	<--
US 2000-247801P	P	20001114	<--
US 2000-247802P	P	20001114	<--
US 2000-247803P	P	20001114	<--
US 2000-247804P	P	20001114	<--
WO 2001-US26142	W	20010822	<--

AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the composition to the patient. The peptide is a homopolymer of a naturally occurring amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)n-cephalexin was prepared from Glu(OBut)NCA and cephalexin hydrochloride.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 18 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:122837 CAPLUS
DOCUMENT NUMBER: 136:189346
TITLE: Medical electropowders for inhalers
INVENTOR(S): Nilsson, Thomas; Nilsson, Lars-Gunnar
PATENT ASSIGNEE(S): Microdrug A.-G., Switz.
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002011803	A1	20020214	WO 2001-SE1682	20010727 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
SE 2000002822	A	20020129	SE 2000-2822	20000804 <--
SE 516555	C2	20020129		
US 6696090	B1	20040224	US 2000-636548	20000811 <--
CA 2417225	AA	20020214	CA 2001-2417225	20010727 <--
AU 2001082743	A5	20020218	AU 2001-82743	20010727 <--
EP 1309369	A1	20030514	EP 2001-961481	20010727 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012903	A	20030701	BR 2001-12903	20010727 <--
JP 2004505685	T2	20040226	JP 2002-517135	20010727 <--

PRIORITY APPLN. INFO.: SE 2000-2822 A 20000804 <--

WO 2001-SE1682 W 20010727 <--

AB A method and a process are disclosed for preparation of medical electro-powders. The electro-powder results from prepns. of chemical and biol. substances to form electro-powders suitable for electrostatic charging and dosing for functionality in a dry powder inhaler device. The electro-powder resulting from the method and process forms an active powder substance or a dry powder medical formulation with a fine particle fraction representing of the order 50 or more of the content having a size ranging between 0,5-5 μm and provides electrostatic properties with an absolute specific charge per mass after charging of the order 0.1x10-6 to 25x10-6 C/g and presenting a charge decay rate constant Q50 > 0.1 s with a tap d. of less than 0.9 g/mL and a water activity aw of less than 0.5. In the processing the active substance is a generally pharmacol. active chemical or biol. substance, for instance a polypeptide or any other corresponding substance selected alone or mixed or blended together with one or more excipients being a compound to improve electrostatic properties of the medical dry powder substance or dry powder medical formulation. Further the electro-powder may even be formed as a micro-encapsulation by coating micronized powder with the excipient in such a way that the active substance is capsulated whereby the powder electrostatic properties mainly comes from the excipient. Terbutaline sulfate, used for asthma treatment, was micronized and analyzed for particle size.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 19 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:89782 CAPLUS
DOCUMENT NUMBER: 136:139841
TITLE: A medicinal aerosol formulation containing a particulate drug
INVENTOR(S): Adjei, Akwete L.; Cutie, Anthony J.
PATENT ASSIGNEE(S): Aeropharm Technology, Inc., USA
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002007672	A2	20020131	WO 2000-US42625	20001207 <--
WO 2002007672	A3	20020627		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001047123	A5	20020205	AU 2001-47123	20001207 <--

PRIORITY APPLN. INFO.: US 2000-619183 A 20000719 <--
WO 2000-US42625 W 20001207 <--

AB This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a particulate drug, or combination of at least two particulate drugs a propellant and a stabilizing agent comprising a water addition (no data).

L10 ANSWER 20 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:780692 CAPLUS
DOCUMENT NUMBER: 135:327352
TITLE: Medicaments for treating respiratory disorders

comprising formoterol and fluticasone
INVENTOR(S): Sanders, Mark
PATENT ASSIGNEE(S): Innovata Biomed Limited, UK
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001078735	A1	20011025	WO 2001-GB1656	20010412 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2405599	AA	20011025	CA 2001-2405599	20010412 <--
EP 1274433	A1	20030115	EP 2001-925665	20010412 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531123	T2	20031021	JP 2001-576035	20010412 <--
US 2003026766	A1	20030206	US 2002-9956	20020412 <--
ZA 2002008804	A	20040209	ZA 2002-8804	20021030 <--

PRIORITY APPLN. INFO.:
GB 2000-9046 A 20000413 <--
GB 2001-5967 A 20010310 <--
WO 2001-GB1656 W 20010412 <--

AB There is described a method of treating or alleviating a respiratory disorder which comprises administering an effective amount of the active ingredients formoterol, or a pharmaceutically acceptable salt thereof, and fluticasone, or a pharmaceutically acceptable ester thereof, sep., sequentially or simultaneously, provided that the active ingredients comprise sep. compns. There is also described a dry powder inhaler containing formoterol, or a pharmaceutically acceptable salt thereof, and fluticasone, or a pharmaceutically acceptable ester thereof, which may be administered sep., sequentially or simultaneously, provided that they are administered as sep. compns. Inhibition of Sephadex-induced edema by formoterol and fluticasone in the rats' lungs were studied.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 21 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:713820 CAPLUS
DOCUMENT NUMBER: 135:262267
TITLE: Preparation of pharmaceutical powder agglomerates
INVENTOR(S): Yang, Tsong-toh
PATENT ASSIGNEE(S): Schering Corp., USA
SOURCE: U.S. Pat. Appl. Publ., 18 pp., Cont. of U.S. Ser. No. 42,973, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001024641	A1	20010927	US 2001-824377	20010402 <--
US 6503537	B2	20030107		

US 2001051187	A1	20011213	US 2001-901205		20010709 <--
US 6495167	B2	20021217			
US 2003085480	A1	20030508	US 2002-238423		20020910 <--
US 2003157184	A1	20030821	US 2002-326327		20021219 <--
US 2004109828	A1	20040610	US 2003-725845		20031202 <--
US 2005123608	A1	20050609	US 2005-28788		20050104 <--
PRIORITY APPLN. INFO.:			US 1997-41055P	P	19970320 <--
			US 1998-42973	B1	19980317 <--
			US 2001-824377	A1	20010402 <--
			US 2001-901205	A1	20010709 <--
			US 2002-238423	B1	20020910
			US 2002-326327	A1	20021219

AB The invention relates to a method of producing an agglomerate of drug and solid binder. The process involves producing individual agglomerate particles and then converting the convertible amorphous content of same, following agglomeration, by the application of, e.g., moisture. Agglomerates capable of conversion as well as the finished agglomerates and oral and nasal dosing systems including same are also contemplated. The process produces agglomerates which are rugged but which will produce an acceptable fine particle fraction during dosing. Micronization of mometasone and lactose were carried out at 20% RH and 21°. The powders were blended and the bulk d. was determined

L10 ANSWER 22 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:713112 CAPLUS
DOCUMENT NUMBER: 135:262244
TITLE: Stabilized dry powder formulations containing formoterol
INVENTOR(S): Ward, Gary
PATENT ASSIGNEE(S): Dura Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 9 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001070198	A1	20010927	WO 2001-US7991		20010313 <--
W: AU, BR, CA, CN, CZ, FI, HU, IL, JP, MX, NO, NZ, RU, SG					
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR					
US 6369115	B1	20020409	US 2000-528519		20000320 <--
CA 2404064	AA	20010927	CA 2001-2404064		20010313 <--
EP 1272162	A1	20030108	EP 2001-916609		20010313 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR					
JP 2003527412	T2	20030916	JP 2001-568396		20010313 <--
PRIORITY APPLN. INFO.:			US 2000-528519	A	20000320 <--
			WO 2001-US7991	W	20010313 <--

AB A dry powder formulation for treatment of pulmonary conditions, via inhalation, includes an effective amount of formoterol or a salt or solvate thereof, in a dry powder form, an effective amount of fluticasone, in a dry powder form, and an excipient. A method for preparing a phys. stable dry powder formulation for inhalation includes the steps of micronizing a first active polar drug, a second active non-polar drug, and a polar excipient. The second non-polar active drug is first blended with the excipient to form an intermediate mixture The intermediate mixture is then blended with the first active polar drug. The increased separation of the polar drug and polar excipient stabilizes the formulation. In preparing the formulation, formoterol fumarate dihydrate and fluticasone are micronized and mixed in the proportions of 1:2 to 1:100. The fluticasone was blended with an excipient mixture and filled into a powder storage device, such as

blister disks or cassettes.
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 23 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:564809 CAPLUS
DOCUMENT NUMBER: 135:142240
TITLE: A method of administering a medicinal aerosol formulation
INVENTOR(S): Adjei, Akwete L.; Stefanos, Simon; Zhu, Yaping
PATENT ASSIGNEE(S): Aeropharm Technology, Inc., USA
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001054664	A1	20010802	WO 2001-US116	20010102 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6596261	B1	20030722	US 2000-702194	20001030 <--
CA 2396781	AA	20010802	CA 2001-2396781	20010102 <--
EP 1250127	A1	20021023	EP 2001-946786	20010102 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003521492	T2	20030715	JP 2001-555643	20010102 <--
AU 775634	B2	20040805	AU 2001-29262	20010102 <--

PRIORITY APPLN. INFO.:			
US 2000-177982P	P	20000125	<--
US 2000-702194	A	20001030	<--
US 1998-158369	A	19980922	<--
WO 2001-US116	W	20010102	<--

AB A method of treating in a human or animal a condition capable of treatment by oral or nasal inhalation has been found. The method comprises administering a medicinal aerosol formulation comprising a selected medicament under conditions where the amount of the selected drug delivered to the site of action, e.g. the lungs, is maximized. After intrapulmonary and i.v. administration of 7.5, and 5.0 μg/kg amylin, resp., to rabbits the half life of the drug in the body was 26.38 and 17.17 min, resp.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 24 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:283949 CAPLUS
DOCUMENT NUMBER: 134:311218
TITLE: Synthesis and use of heterocyclic sodium/proton exchange inhibitors
INVENTOR(S): Ahmad, Saleem; Wu, Shung C.; O'Neil, Steven V.; Ngu, Khehyong; Atwal, Karnail S.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 221 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027107	A2	20010419	WO 2000-US27461	20001002 <--
WO 2001027107	A3	20020124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6887870	B1	20050503	US 2000-669298	20000925 <--
CA 2388813	AA	20010419	CA 2000-2388813	20001002 <--
EP 1224183	A2	20020724	EP 2000-968723	20001002 <--
EP 1224183	B1	20051228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000014725	A	20030617	BR 2000-14725	20001002 <--
JP 2003527331	T2	20030916	JP 2001-530325	20001002 <--
NZ 517668	A	20040924	NZ 2000-517668	20001002 <--
AT 314364	E	20060115	AT 2000-968723	20001002 <--
ZA 2002002479	A	20040727	ZA 2002-2479	20020327 <--
NO 2002001717	A	20020610	NO 2002-1717	20020411 <--
US 2005137216	A1	20050623	US 2005-46993	20050131 <--

PRIORITY APPLN. INFO.:			US 1999-158755P	P 19991012 <--
			US 2000-669298	A3 20000925 <--
			WO 2000-US27461	W 20001002 <--

OTHER SOURCE(S): MARPAT 134:311218

GI



I II

AB Compds. of formula I [wherein; n is 1-5; X is N or CR5, where R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl group; R1 is H, alk(en)(yn)yl, alk(enyl)(ynyl)oxy, (aryl or alkyl)3Si, cycloalk(en)yl, (aryl)amino, aryl(alkyl), cycloheteroaryl, etc.; R2, R3 and R4 are any of the groups set out for R1 and optionally substituted with 1 to 5 substituents which may be the same or different and when X is N, R1 is preferably aryl or heteroaryl] are claimed. Several hundred examples are disclosed. Synthesis of II proceeds via cyclopropanation of the cinnamate derived from the olefination between 3,5-dichlorobenzaldehyde and t-butyldiethylphosphonoacetate. The intermediate tert-Bu ester is converted to the corresponding α-chloroketone and reacted with acetyl guanidine to provide II in a total of 5 steps. Compds. I are said to be sodium/proton exchange inhibitors (NHE). Pharmaceutical combinations are claimed using I and certain antihypertensive agents, β-adrenergic agonists, hypolipidemic agents, antidiabetic agents, antiobesity agents, etc. Compds. I are useful as antianginal and cardioprotective agents and provide a method for

preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia.

L10 ANSWER 25 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:152458 CAPLUS
DOCUMENT NUMBER: 134:183526
TITLE: Method to produce powders for pulmonary or nasal administration
INVENTOR(S): Woolfe, Austen John; Zeng, Xian Ming; Langford, Alan
PATENT ASSIGNEE(S): Norton Healthcare Ltd., UK
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001013885	A1	20010301	WO 2000-GB3230	20000821 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2382216	AA	20010301	CA 2000-2382216	20000821 <--
JP 2003526629	T2	20030909	JP 2001-518024	20000821 <--

PRIORITY APPLN. INFO.: US 1999-150095P P 19990820 <--
WO 2000-GB3230 W 20000821 <--

AB A pharmaceutical formulation comprises a mixture of two or more drugs optionally together with one or more excipients, the mixture being formed by the steps of: co-crystallization or co-precipitation of the drugs followed by micronization or milling to produce a uniform powder having a particle size and other properties suitable for formulation for pulmonary or nasal administration. An aqueous solution of 5% salbutamol sulfate:ipratropium bromide (10:1) mixture was prepared and was spray dried. The diameter of particles was less than 3 μm.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 26 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:60975 CAPLUS
DOCUMENT NUMBER: 134:305151
TITLE: Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers
AUTHOR(S): Palmqvist, Mona; Arvidsson, Peter; Beckman, Ola; Peterson, Stefan; Lotvall, Jan
CORPORATE SOURCE: Lung Pharmacology Group, Department of Respiratory, Medicine and Allergology, Goteborg University, Goeteborg, SE-413 46, Swed.
SOURCE: Pulmonary Pharmacology & Therapeutics (**2001**), 14(1), 29-34
CODEN: PPTHFJ; ISSN: 1094-5539
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Combinations of inhaled glucocorticoids and long-acting β2-agonists in the same inhaler device have become available in recent years. In this double-blind, randomized, placebo-controlled and crossover study we have

evaluated the onset of action of budesonide and formoterol in a single inhaler (Symbicort Turbuhaler) and that of the fixed combination of salmeterol and fluticasone (Seretide Diskus). Thirty patients with a mean FEV1of 2.54 l (range: 1.48-4.28) and a mean inclusion reversibility in FEV1of 19.1% were included. Single doses of budesonide/formoterol 160/4.5 μg and 2+ (160/4.5) μg, salmeterol/fluticasone 50/250 μg, or placebo were given. Serial measurements of FEV1were performed over 3 h. The combination of one or two inhalations of budesonide/formoterol showed a faster onset of action than salmeterol/fluticasone, both evaluated as mean FEV1at 3 min (2.74, 2.75 and 2.56 l resp. P<0.001 for both doses of budesonide/formoterol), or as average FEV1from 0 to 15 min (2.80, 2.83 and 2.67 l resp. P<0.001 for both doses of budesonide/formoterol). For placebo, mean FEV1at 3 min was 2.46 l, and the average FEV1at 0-15 min was 2.50 l. Furthermore, budesonide/formoterol at both doses resulted in higher FEV1than salmeterol/fluticasone at 3 h. We conclude that the combination of budesonide/formoterol has a faster onset of action than salmeterol/fluticasone.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 27 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:401693 CAPLUS
DOCUMENT NUMBER: 133:34456
TITLE: A medicinal aerosol formulation
INVENTOR(S): Adjei, Akwete; Cutie, Anthony J.
PATENT ASSIGNEE(S): Aeropharm Technology Incorporated, USA
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033892	A1	20000615	WO 1999-US28644	19991203 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6261539	B1	20010717	US 1998-209228	19981210 <--
CA 2353959	AA	20000615	CA 1999-2353959	19991203 <--
EP 1135173	A1	20010926	EP 1999-965104	19991203 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 749636	B2	20020627	AU 2000-31089	19991203 <--
JP 2003521459	T2	20030715	JP 2000-586382	19991203 <--

PRIORITY APPLN. INFO.: US 1998-209228 A 19981210 <--
WO 1999-US28644 W 19991203 <--

AB This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a particulate drug, a propellant and a stabilizing agent comprising a water addition Generally the formulations can be prepared by combining (1) the drug, e.g. triamcinolone acetonide, in an amount sufficient to provide a plurality of therapeutically EDs, (2) the water addition in an amount effective to stabilize each of the formulations, (3) the propellant in an amount sufficient to propel a plurality of doses from an aerosol canister, and (4) any further optional components, e.g. ethanol as a cosolvent and dispersing the components.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 28 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:351357 CAPLUS
DOCUMENT NUMBER: 133:9107
TITLE: Dry powder for inhalation
INVENTOR(S): Keller, Manfred; Mueller-Walz, Rudi
PATENT ASSIGNEE(S): Skyepharma A.-G., Switz.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000028979	A1	20000525	WO 1999-CH528	19991110 <--
W: AU, CA, CN, CZ, HU, IN, JP, NO, NZ, PL, RO, RU, SK, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2347856	AA	20000525	CA 1999-2347856	19991110 <--
AU 9964578	A1	20000605	AU 1999-64578	19991110 <--
AU 756852	B2	20030123		
EP 1131059	A1	20010912	EP 1999-952212	19991110 <--
EP 1131059	B1	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO				
JP 2002529498	T2	20020910	JP 2000-582027	19991110 <--
NZ 511527	A	20021025	NZ 1999-511527	19991110 <--
EP 1283036	A1	20030212	EP 2002-25796	19991110 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AT 233550	E	20030315	AT 1999-952212	19991110 <--
PT 1131059	T	20030731	PT 1999-952212	19991110 <--
ES 2192866	T3	20031016	ES 1999-952212	19991110 <--
RU 2221552	C2	20040120	RU 2001-116074	19991110 <--
SK 284889	B6	20060202	SK 2001-632	19991110 <--
ZA 2001003627	A	20010509	ZA 2001-3627	20010504 <--
NO 2001002346	A	20010626	NO 2001-2346	20010511 <--
US 6645466	B1	20031111	US 2001-831011	20010809 <--
US 2004202616	A1	20041014	US 2003-628965	20030728 <--

PRIORITY APPLN. INFO.:			
	CH 1998-2286	A	19981113 <--
	EP 1999-952212	A3	19991110 <--
	WO 1999-CH528	W	19991110 <--
	US 2001-831011	A1	20010809 <--

AB The moisture resistance of dry powder formulations for inhalation, which contain a pharmaceutically inert carrier of noninhalable particle size and a finely divided pharmaceutical substance of inhalable particle size, is improved and the storage stability of the formulations is increased by adding Mg stearate to minimize the deleterious effect of moisture on fine particle dose and fine particle fraction even under relatively extreme temperature and humidity conditions. Thus, 198.46 g lactose-H2O (particle size 100% <200 μm, 50% <125 μm, 10% <75 μm) was mixed with 1 g sieved Mg stearate, then with 0.54 g formoterol fumarate-2H2O, and loaded into a multidose dry powder inhaler.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 29 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:209955 CAPLUS
DOCUMENT NUMBER: 132:241977
TITLE: Medicinal aerosol formulation
INVENTOR(S): Adjei, Akwete; Cutie, Anthony J.

PATENT ASSIGNEE(S): Aeropharm Technology Incorporated, USA
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000016814	A1	20000330	WO 1999-US21510	19990917 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6136294	A	20001024	US 1998-158369	19980922 <--
US 6136294	C1	20020924		
CA 2344816	AA	20000330	CA 1999-2344816	19990917 <--
AU 9959267	A1	20000410	AU 1999-59267	19990917 <--
AU 745554	B2	20020321		
EP 1123120	A1	20010816	EP 1999-946974	19990917 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002526459	T2	20020820	JP 2000-573775	19990917 <--

PRIORITY APPLN. INFO.: US 1998-158369 A 19980922 <--
WO 1999-US21510 W 19990917 <--

AB This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a particulate drug, a propellant, and stabilizing agent selected from an amino acid, an amino acid derivative and a mixture of the foregoing. An example amino acid stabilizer is glycine, an example medicament is albuterol, and example propellant is 1,1,1,2-tetrafluoroethane.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 30 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:116874 CAPLUS
DOCUMENT NUMBER: 132:156861
TITLE: Medicinal aerosol formulations
INVENTOR(S): Keller, Manfred; Herzog, Kurt; Mueller-Walz, Rudi; Kraus, Holger
PATENT ASSIGNEE(S): Jago Research A.-G., Switz.
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000007567	A1	20000217	WO 1999-CH360	19990802 <--
W: AU, CA, CN, IN, JP, NO, NZ, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2338680	AA	20000217	CA 1999-2338680	19990802 <--
AU 9948939	A1	20000228	AU 1999-48939	19990802 <--
AU 749697	B2	20020704		
EP 1102579	A1	20010530	EP 1999-932599	19990802 <--

EP 1102579 B1 20030319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
JP 2002522374 T2 20020723 JP 2000-563253 19990802 <--
NZ 509489 A 20021025 NZ 1999-509489 19990802 <--
AT 234604 E 20030415 AT 1999-932599 19990802 <--
PT 1102579 T 20030731 PT 1999-932599 19990802 <--
ES 2193726 T3 20031101 ES 1999-932599 19990802 <--
ZA 2001000569 A 20010730 ZA 2001-569 20010119 <--
NO 2001000531 A 20010131 NO 2001-531 20010131 <--
US 6475467 B1 20021105 US 2001-744798 20010420 <--
PRIORITY APPLN. INFO.: CH 1998-1633 A 19980804 <--
WO 1999-CH360 W 19990802 <--

AB Pharmaceutically acceptable solid salts containing cromoglycic acid and/or nedocromil as a vehicle, at concns. which are not therapeutically and prophylactically active, are used in suspension aerosol formulations of pharmaceutical active ingredients in fluoroalkane propellants to improve the dispersion characteristics, increase the phys. and chemical stability of moisture-sensitive active ingredients, allow for accurate dosing of active ingredients even at low dosage, and generally eliminate the need for surface-active agents. Thus, 6 g micronized formoterol fumarate and 12 g micronized di-Na cromoglycate were mixed in an evacuated vessel with fluoroalkane HFA 134a 35, HFA 227 35 kg, and EtOH 3 weight%, and the suspension was homogenized and dispensed into Al vials equipped with dosing valves.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 31 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:98270 CAPLUS
DOCUMENT NUMBER: 132:141967
TITLE: Medicinal aerosol formulations
INVENTOR(S): Keller, Manfred; Herzog, Kurt; Mueller-Walz, Rudi; Kraus, Holger
PATENT ASSIGNEE(S): Jago Research A.-G., Switz.
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006121	A1	20000210	WO 1999-CH337	19990722 <--
W: AU, CA, CN, IN, JP, NO, NZ, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2338753	AA	20000210	CA 1999-2338753	19990722 <--
AU 9945989	A1	20000221	AU 1999-45989	19990722 <--
AU 748867	B2	20020613		
EP 1100465	A1	20010523	EP 1999-928996	19990722 <--
EP 1100465	B1	20041124		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002521424	T2	20020716	JP 2000-561978	19990722 <--
NZ 509328	A	20021126	NZ 1999-509328	19990722 <--
AT 283033	E	20041215	AT 1999-928996	19990722 <--
ES 2234266	T3	20050616	ES 1999-928996	19990722 <--
ZA 2001000408	A	20010727	ZA 2001-408	20010115 <--
NO 2001000391	A	20010323	NO 2001-391	20010123 <--
US 6585958	B1	20030701	US 2001-744379	20010413 <--

PRIORITY APPLN. INFO.: CH 1998-1565 A 19980724 <--
WO 1999-CH337 W 19990722 <--

AB A compression-fluidized propellant mixture for aerosols, containing N2O and a C1-3 hydrofluoroalkane, especially 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane, improves the wetting properties of pharmaceutical active ingredients so that the difficulties associated with the use of hydrofluoroalkanes in the preparation of suspension and solution aerosols can be overcome and improved medicinal aerosol formulations can be obtained. Using N2O, it is also possible to influence pressure and thus particle size distribution in a targeted manner and to improve the storage stability of oxidation-sensitive active ingredients by displacement of O2 out of the hydrofluoroalkanes. If desired the propellant mixture can also contain CO2. Thus, 8.5 kg HFA 227 containing 3 weight% EtOH was gassed with N2O, pressurized to 5 bar at 20°, and added to 100 g di-Na cromoglycate in an evacuated vessel. After homogenizing, the suspension was dispensed into Al vials with dosing valves.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 32 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:96087 CAPLUS
DOCUMENT NUMBER: 132:141964
TITLE: Two-piece capsule for pharmaceutical preparations for dry powder inhalers
INVENTOR(S): Hochrainer, Dieter; Eckert, Josef
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: Ger. Offen., 10 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19835346	A1	20000210	DE 1998-19835346	19980805 <--
CA 2338323	AA	20000217	CA 1999-2338323	19990803 <--
WO 2000007572	A2	20000217	WO 1999-EP5614	19990803 <--
WO 2000007572	A3	20000511		
W: AU, BG, BR, CA, CN, CZ, EE, HU, ID, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9957304	A1	20000228	AU 1999-57304	19990803 <--
AU 763266	B2	20030717		
BR 9912748	A	20010515	BR 1999-12748	19990803 <--
EP 1100474	A2	20010523	EP 1999-944325	19990803 <--
EP 1100474	B1	20020717		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200100355	T2	20010621	TR 2001-200100355	19990803 <--
EE 200100073	A	20020617	EE 2001-73	19990803 <--
EE 4451	B1	20050415		
JP 2002522378	T2	20020723	JP 2000-563258	19990803 <--
AT 220542	E	20020815	AT 1999-944325	19990803 <--
PT 1100474	T	20021231	PT 1999-944325	19990803 <--
ES 2180325	T3	20030201	ES 1999-944325	19990803 <--
SK 283568	B6	20030911	SK 2001-169	19990803 <--
NZ 509977	A	20031128	NZ 1999-509977	19990803 <--
TW 221420	B1	20041001	TW 1999-88113240	19990803 <--
BG 105189	A	20010731	BG 2001-105189	20010126 <--
BG 64115	B1	20040130		
ZA 2001000796	A	20020529	ZA 2001-796	20010129 <--
NO 2001000535	A	20010131	NO 2001-535	20010131 <--

US 2001008637	A1	20010719	US 2001-800647		20010307 <--
HK 1037975	A1	20041210	HK 2001-108874		20011219 <--
US 2004131668	A1	20040708	US 2003-740225		20031218 <--
PRIORITY APPLN. INFO.:			DE 1998-19835346	A	19980805 <--
			US 1998-113214P	P	19981222 <--
			US 1999-365912	A1	19990803 <--
			WO 1999-EP5614	W	19990803 <--
			US 2001-800647	A1	20010307 <--

AB Capsules for pharmaceutical prepns. for use in dry powder inhalers with increased drug safety consist of water-insol., hydrophobic plastics which do not substantially affect the pharmaceutical quality of the contents, but improve their useful life and/or the geog. range of their use (especially with regard to humidity). The capsules have a Shore hardness of 65-73, such that during opening or puncture of the capsule, no capsule fragments are produced which could be inhaled, and that the capsule cannot spontaneously reseal after opening or puncture. They can withstand a force of ≤15 N in all directions during manufacture, filling, packing, and transport. The capsules have a permeability for water vapor of <1.3 + 10-14 kg/(m2 s Pa).

L10 ANSWER 33 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:763852 CAPLUS
DOCUMENT NUMBER: 132:15622
TITLE: Tightly-compacted solid medicament stock for inhalation delivery
INVENTOR(S): Fleischer, Wolfgang; Reimer, Karen
PATENT ASSIGNEE(S): Euroceltique S.A., Luxembourg
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9961003	A1	19991202	WO 1999-EP3680		19990527 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2332369	AA	19991202	CA 1999-2332369		19990527 <--
AU 9942667	A1	19991213	AU 1999-42667		19990527 <--
AU 747877	B2	20020530			
BR 9911070	A	20010206	BR 1999-11070		19990527 <--
EP 1083886	A1	20010321	EP 1999-953285		19990527 <--
EP 1083886	B1	20030402			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
DE 29923766	U1	20010712	DE 1999-29923766		19990527 <--
JP 2002516269	T2	20020604	JP 2000-550463		19990527 <--
AT 235895	E	20030415	AT 1999-953285		19990527 <--
RU 2202340	C2	20030420	RU 2000-131695		19990527 <--
AT 319427	E	20060315	AT 1999-926446		19990527 <--
PRIORITY APPLN. INFO.:			US 1998-86895P	P	19980527 <--
			EP 1999-953285	A	19990527 <--
			WO 1999-EP3680	W	19990527 <--

AB A drug delivery system comprises a tightly-compacted solid medicament stock having an isotropic solid state structure, containing an active agent.The stock is suitable for the generation of inhalable particles

containing the active agent. The active agent is associated with a particulate carrier material, preferably liposomes. Suitable active agents are β2-sympathomimetics, corticosteroids, anticholinergics, inflammation inhibitors and antiseptics.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 34 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:635641 CAPLUS
DOCUMENT NUMBER: 129:265477
TITLE: Preparation of powder agglomerates of drugs and solid binders
INVENTOR(S): Yang, Tsong-toh
PATENT ASSIGNEE(S): Schering Corp., USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9841193	A1	19980924	WO 1998-US3799	19980316 <--
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2282360	AA	19980924	CA 1998-2282360	19980316 <--
CA 2282360	C	20041109		
CA 2481868	AA	19980924	CA 1998-2481868	19980316 <--
AU 9865378	A1	19981012	AU 1998-65378	19980316 <--
AU 741783	B2	20011206		
EP 969816	A1	20000112	EP 1998-911423	19980316 <--
EP 969816	B1	20041215		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO				
JP 2000510478	T2	20000815	JP 1998-540530	19980316 <--
NZ 337443	A	20010427	NZ 1998-337443	19980316 <--
EP 1393721	A1	20040303	EP 2003-20466	19980316 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO				
CN 1552310	A	20041208	CN 2004-10032204	19980316 <--
AT 284677	E	20050115	AT 1998-911423	19980316 <--
PT 969816	T	20050429	PT 1998-911423	19980316 <--
ES 2234102	T3	20050616	ES 1998-911423	19980316 <--
CZ 295460	B6	20050817	CZ 1999-3233	19980316 <--
SK 284919	B6	20060202	SK 1999-1280	19980316 <--
ZA 9802254	A	19980917	ZA 1998-2254	19980317 <--
TW 221778	B1	20041011	TW 1998-87103951	19980317 <--
NO 9904519	A	19991119	NO 1999-4519	19990917 <--
HK 1021323	A1	20050603	HK 2000-100233	20000114 <--

PRIORITY APPLN. INFO.:			
	US 1997-821129	A	19970320 <--
	CA 1998-2282360	A3	19980316 <--
	EP 1998-911423	A3	19980316 <--
	WO 1998-US3799	W	19980316 <--

AB A method of producing an agglomerate of drug and solid binder is disclosed. The process involves producing individual agglomerate particles and then converting the convertible amorphous content of same, following agglomeration, by the application of, for example, moisture. Agglomerates capable of conversion as well as the finished agglomerates

and oral and nasal dosing systems including same are also contemplated. The process produces agglomerates which are rugged but which will produce an acceptable fine particle fraction during dosing. Agglomerates of lactose monohydrate (I) and mometasone furoate (II) were prepared under the following conditions: micronization of I and II at 21° and 20% relative humidity (RH), storage of micronized lactose at 21° and 20% RH, conversion of powder agglomerates at 25° and 50% RH. The agglomerates had bulk d. of 0.35 g/cm3, and mean particle size of 580 μm and the ratio of II:I was 1:5.8.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 35 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:548518 CAPLUS
DOCUMENT NUMBER: 129:207207
TITLE: Biocompatible polymer for pharmaceutical drug delivery aerosol formulations
INVENTOR(S): Stefely, James S.; Schultz, David W.; Schallinger, Luke E.; Perman, Craig A.; Leach, Chester L.; Duan, Daniel C.
PATENT ASSIGNEE(S): Minnesota Mining and Manufacturing Company, USA
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9834596	A2	19980813	WO 1998-US74	19980204 <--
WO 9834596	A3	19981105		
W: AU, CA, CN, CZ, HU, IL, JP, KR, MX, NZ, PL				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6126919	A	20001003	US 1997-797803	19970207 <--
CA 2279522	AA	19980813	CA 1998-2279522	19980204 <--
AU 9862384	A1	19980826	AU 1998-62384	19980204 <--
AU 724765	B2	20000928		
EP 1014944	A2	20000705	EP 1998-904525	19980204 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001511179	T2	20010807	JP 1998-534404	19980204 <--
NZ 336903	A	20010831	NZ 1998-336903	19980204 <--
CN 1114400	B	20030716	CN 1998-802390	19980204 <--
AU 761559	B2	20030605	AU 2000-51854	20000807 <--
US 6416742	B1	20020709	US 2000-634406	20000809 <--
US 2002164290	A1	20021107	US 2002-78805	20020218 <--

PRIORITY APPLN. INFO.:

US 1997-797803	A	19970207 <--
AU 1998-62384	A3	19980204 <--
WO 1998-US74	W	19980204 <--
US 2000-634406	A3	20000809 <--

AB A medicinal aerosol solution formulation contains a biocompatible polymer containing ≥1 unit [XR1CO] where each R1 is independently selected from organic diyl groups and each X is independently O, S, or a catenary N, a propellant, and a therapeutically effective amount of a drug. The formulation is suitable for oral and/or nasal inhalation. The biocompatible polymers are relatively low mol. weight and are particularly useful for drug solubilization and chemical stabilization as well as for providing sustained release of a drug from a drug delivery system. Thus, poly(L-lactic acid) acetate was prepared and preferred. mol. weight samples were separated by supercrit. fluid fractionation. A medicinal aerosol was formulated using the prepared polymer, butixocort propionate, and HFC 134a propellant. The formulation was delivered into the respiratory track and lungs of adult dogs and metabolite levels were determined An increased drug

residence time in the lungs was observed and attributed to sustained release as result of using the biocompatible polymer.

L10 ANSWER 36 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:548517 CAPLUS
DOCUMENT NUMBER: 129:166237
TITLE: Fluorocarbon propellants for medical aerosol formulations
INVENTOR(S): Keller, Manfred; Herzog, Kurt
PATENT ASSIGNEE(S): Jago Pharma A.-G., Switz.
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9834595	A1	19980813	WO 1998-CH37		19980202 <--
W: AU, CA, JP, NO, NZ, US					
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
CA 2280099	AA	19980813	CA 1998-2280099		19980202 <--
CA 2280099	C	20051227			
AU 9856496	A1	19980826	AU 1998-56496		19980202 <--
AU 718967	B2	20000504			
EP 1014943	A1	20000705	EP 1998-900837		19980202 <--
EP 1014943	B1	20020619			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
NZ 337065	A	20010223	NZ 1998-337065		19980202 <--
JP 2001511160	T2	20010807	JP 1998-533479		19980202 <--
AT 219355	E	20020715	AT 1998-900837		19980202 <--
PT 1014943	T	20021129	PT 1998-900837		19980202 <--
ES 2178817	T3	20030101	ES 1998-900837		19980202 <--
ZA 9800937	A	19980806	ZA 1998-937		19980205 <--
NO 9903773	A	19991004	NO 1999-3773		19990804 <--
US 6461591	B1	20021008	US 1999-355883		19990804 <--
PRIORITY APPLN. INFO.:			CH 1997-248	A	19970205 <--
			WO 1998-CH37	W	19980202 <--

AB A pressure-liquefied propellant mixture for aerosols comprising a fluoridated alkane [especially 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane (HFA 227)] and CO2 improves the wetting properties for pharmaceutical active substances, whereby existing formulation problems with hydrofluoroalkanes in suspension and solution aerosols can be overcome and improved medical aerosol formulations can be obtained. By using CO2, the pressure and hence the particle size distribution can be influenced in a targeted manner, and by removing O2 from the hydrofluoroalkanes the stability during storage of oxidation-sensitive active substances can be improved. Thus, 1.5 kg HFA 227 was gassed with CO2 and added at 6.5 bar and 20° to a solution of beclomethasone dipropionate 2.5 and oleic acid 0.25 in EtOH 55 g in a pressurized vessel; the mixture was dispensed into Al aerosol canisters. The mean aerodynamic particle diameter and fine particle dose per stroke of the dosing valve were .apprx.1.3 μm and 61.5 μg, resp., immediately after filling the canisters; after 6 mo storage at 30° and 70% relative humidity, these values were .apprx.1.3 μm and 71.8 μg, resp.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 37 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:112203 CAPLUS
DOCUMENT NUMBER: 128:172135
TITLE: Aerosol formulations for pharmaceutical and medical

uses
INVENTOR(S): Miller, Fiona
PATENT ASSIGNEE(S): Norton Healthcare Ltd., UK; Miller, Fiona
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9805302	A1	19980212	WO 1997-GB1502	19970603 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2261879	AA	19980212	CA 1997-2261879	19970603 <--
AU 9730381	A1	19980225	AU 1997-30381	19970603 <--
AU 721920	B2	20000720		
EP 918507	A1	19990602	EP 1997-925141	19970603 <--
EP 918507	B1	20020403		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000515536	T2	20001121	JP 1998-507695	19970603 <--
AT 215359	E	20020415	AT 1997-925141	19970603 <--
PT 918507	T	20020930	PT 1997-925141	19970603 <--
ES 2175413	T3	20021116	ES 1997-925141	19970603 <--
NO 9900454	A	19990329	NO 1999-454	19990129 <--

PRIORITY APPLN. INFO.: GB 1996-16237 A 19960801 <--
WO 1997-GB1502 W 19970603 <--

AB The replacement of chlorofluorohydrocarbon propellants in medical aerosols is of the utmost importance to the pharmaceutical industry. A number of formulations have been investigated. The present invention provides a medical aerosol formulation comprising a particular medicament, a fluorocarbon propellant, and a polar co-solvent, such formulation being substantially free of surfactant. Cannisters suitable for delivering such a pharmaceutical formulation are also provided. Micronized salbutamol sulfate was added to ethanol to give a suspension, which was filled into an aerosol canister. The metering valve assembly was crimped on the canister and tetrafluoroethane was filled through the valve, in which the valve capacity was to deliver 100 μg salbutamol per actuation.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 38 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:728984 CAPLUS
DOCUMENT NUMBER: 125:339082
TITLE: Process for the preparation of respirable particles
INVENTOR(S): Jakupovic, Edib; Trofast, Jan
PATENT ASSIGNEE(S): Astra Aktiebolag, Swed.
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9632095		A1	19961017	WO 1996-SE479	19960412 <--
W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
ZA 9602596		A	19961014	ZA 1996-2596	19960401 <--
TW 492877		B	20020701	TW 1996-85103802	19960401 <--
IN 185119		A	20001118	IN 1996-DE723	19960402 <--
IL 117841		A1	20040104	IL 1996-117841	19960408 <--
CA 2217062		AA	19961017	CA 1996-2217062	19960412 <--
AU 9653524		A1	19961030	AU 1996-53524	19960412 <--
AU 694863		B2	19980730		
EP 820276		A1	19980128	EP 1996-910285	19960412 <--
EP 820276		B1	20030102		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1186428		A	19980701	CN 1996-194372	19960412 <--
CN 1102383		B	20030305		
JP 11503448		T2	19990326	JP 1996-530963	19960412 <--
AT 230257		E	20030115	AT 1996-910285	19960412 <--
PT 820276		T	20030430	PT 1996-910285	19960412 <--
ES 2188750		T3	20030701	ES 1996-910285	19960412 <--
US 6221398		B1	20010424	US 1996-669477	19960710 <--
NO 9704557		A	19971002	NO 1997-4557	19971002 <--
NO 316209		B1	20031229		
PRIORITY APPLN. INFO.:				SE 1995-1384 A	19950413 <--
				WO 1996-SE479 W	19960412 <--

AB A process for producing a pharmaceutical powder for inhalation comprising crystalline particles of an inhalation compound, comprising dissolving an inhalation compound in a solvent; and introducing the solution containing the inhalation compound in droplet form or as a jet stream, into an anti-solvent which is miscible with the solvent and which is under agitation.

L10 ANSWER 39 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	1996:476908 CAPLUS
DOCUMENT NUMBER:	125:123754
TITLE:	Aerosol drug formulations containing hydrofluoralkane propellants and surfactants
INVENTOR(S):	Baeckstroem, Kjell; Dahlbaeck, Magnus; Johansson, Ann; Kaellstrand, Goeran; Lindqvist, Elisabet
PATENT ASSIGNEE(S):	Astra Aktiebolag, Swed.
SOURCE:	PCT Int. Appl., 17 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9619198	A1	19960627	WO 1995-SE1542	19951219 <--
W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9510754	A	19960624	ZA 1995-10754	19951218 <--
CA 2206782	AA	19960627	CA 1995-2206782	19951219 <--
AU 9643593	A1	19960710	AU 1996-43593	19951219 <--
AU 702880	B2	19990311		

EP 806940	A1	19971119	EP 1995-942343		19951219 <--
EP 806940	B1	20030409			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV					
CN 1170356	A	19980114	CN 1995-196953		19951219 <--
CN 1088580	B	20020807			
BR 9510510	A	19980707	BR 1995-10510		19951219 <--
HU 77775	A2	19980828	HU 1998-483		19951219 <--
CZ 288146	B6	20010516	CZ 1997-1947		19951219 <--
AT 236617	E	20030415	AT 1995-942343		19951219 <--
IL 116460	A1	20031031	IL 1995-116460		19951219 <--
US 6932962	B1	20050823	US 1996-601005		19951219 <--
NO 9702681	A	19970611	NO 1997-2681		19970611 <--
NO 318229	B1	20050221			
FI 9702655	A	19970619	FI 1997-2655		19970619 <--
JP 2006124404	A2	20060518	JP 2006-29673		20060207 <--
PRIORITY APPLN. INFO.:			SE 1994-4469	A	19941222 <--
			SE 1995-2452	A	19950706 <--
			JP 1996-519732	A3	19951219 <--
			WO 1995-SE1542	W	19951219 <--

AB Aerosol formulations suitable for use in pressurized metered dose inhalers comprise a hydrofluoralkane propellant, a medicament for inhalation and a surfactant which is a C8-C16 fatty acid or salt thereof, a bile salt, a phospholipid, or an alkyl saccharide. Micronized formoterol fumarate and micronized Na taurocholate were added to a plastic-coated glass bottle. The bottle was chilled to -40° with a mixture of CO2 ice and isopropanol and then chilled 1,1,1,2-tetrafluoroethane was added. The bottle was sealed with a metering valve and treated in an ultrasonic bath for 10 min to give a good suspension.

L10 ANSWER 40 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:528673 CAPLUS
DOCUMENT NUMBER: 122:274076
TITLE: Process for conditioning substances
INVENTOR(S): Trofast, Eva Ann-Christin; Briggner, Lars-Erik
PATENT ASSIGNEE(S): Astra Aktiebolag, Swed.
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9505805	A1	19950302	WO 1994-SE780	19940825 <--
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9405675	A	19960429	ZA 1994-5675	19940729 <--
TW 427916	B	20010401	TW 1994-83107152	19940804 <--
IL 110698	A1	20021110	IL 1994-110698	19940818 <--
CA 2170394	AA	19950302	CA 1994-2170394	19940825 <--
CA 2170394	C	20041012		
AU 9476264	A1	19950321	AU 1994-76264	19940825 <--
AU 681186	B2	19970821		
BR 9407320	A	19960416	BR 1994-7320	19940825 <--
EP 717616	A1	19960626	EP 1994-926421	19940825 <--
EP 717616	B1	20010321		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1133004	A	19961009	CN 1994-193793	19940825 <--

CN 1049333	B	20000216				
HU 74000	A2	19961028	HU 1996-447			19940825 <--
HU 217770	B	20000428				
JP 09501930	T2	19970225	JP 1994-507516			19940825 <--
JP 2978247	B2	19991115				
PL 176749	B1	19990730	PL 1994-313142			19940825 <--
RU 2148992	C1	20000520	RU 1996-105935			19940825 <--
AT 199828	E	20010415	AT 1994-926421			19940825 <--
ES 2156158	T3	20010616	ES 1994-926421			19940825 <--
PT 717616	T	20010830	PT 1994-926421			19940825 <--
CZ 289018	B6	20011017	CZ 1996-544			19940825 <--
SK 283146	B6	20030304	SK 1996-234			19940825 <--
US 5709884	A	19980120	US 1995-379471			19950130 <--
NO 9600744	A	19960223	NO 1996-744			19960223 <--
NO 312433	B1	20020513				
FI 9600869	A	19960226	FI 1996-869			19960226 <--
CN 1195523	A	19981014	CN 1997-123049			19971126 <--
CN 1090019	B	20020904				
HK 1016493	A1	20030425	HK 1999-101600			19990414 <--
GR 3036106	T3	20010928	GR 2001-400955			20010621 <--
PRIORITY APPLN. INFO.:			SE 1993-2777	A		19930827 <--
			WO 1994-SE780	W		19940825 <--

AB The present invention relates to a process for providing a stable crystalline form to a fine-grained substance or a substance mixture, which can be produced, stored and used while maintaining the aerodynamic properties required for inhalation of such a substance or a substance mixture, by a) in case of a substance mixture, preparing a homogeneous mixture of the substances; b) micronizing, direct precipitating or diminishing by any conventional method the substance or substance mixture into a particle size required for inhalation, the particle size being less than 10 μm; c) optionally preparing a homogeneous mixture of the desired substances when each substance has been introduced from stage b) as sep. fine-grained particles; d) conditioning said substance or substance mixture by treatment with a water containing vapor phase in a controlled fashion; and e) drying.

L10 ANSWER 41 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1991:589788 CAPLUS
DOCUMENT NUMBER: 115:189788
TITLE: Hydrofluorocarbon propellants for pharmaceutical aerosols
INVENTOR(S): Steele, Gerald; Somani, Asit; Lim, Joseph Geok Paan
PATENT ASSIGNEE(S): Fisons PLC, UK
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9111173	A1	19910808	WO 1991-GB133	19910130 <--
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
IL 97065	A1	19940125	IL 1991-97065	19910128 <--
CA 2074495	AA	19910803	CA 1991-2074495	19910130 <--
CA 2074495	C	20031216		
ZA 9100696	A	19911030	ZA 1991-696	19910130 <--
EP 513127	A1	19921119	EP 1991-903548	19910130 <--
EP 513127	B1	19950719		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05503523	T2	19930610	JP 1991-503797	19910130 <--
JP 2858948	B2	19990217		

```
     ES 2075956           T3    19951016    ES 1991-903548          19910130 <--
     US 6582677           B1    20030624    US 1996-766580          19961212 <--
PRIORITY APPLN. INFO.:                      GB 1990-2351        A   19900202 <--
                                            GB 1990-23655       A   19901031 <--
                                            GB 1990-26476       A   19901205 <--
                                            WO 1991-GB133       W   19910130 <--
                                            US 1992-916107      B1  19920722 <--
                                            US 1994-355106      B1  19941213 <--
AB   A pressurized aerosol composition comprises a liquefied hydrofluorocarbon
     propellant containing substantially no nonhydrofluorocarbon solvent having
     dispersed therein a medicament and a fluorinated surfactant.  The
     propellants are substantially taste- and odor-free and have suitable vapor
     pressures for the administration of medicaments by inhalation, yet are
     environmentally safe and acceptable.  Thus, a composition containing
nedocromil Na
     0.200, FC 431 (fluorinated acrylic polymer) 0.061, and CF3CFH2 11.979 g
     was filled into Al aerosol canister.


=> s beclomethasone or flunisolide or triamcinolone acetonide or dexamethasone or
tipredane or ciclesonid or refloponide or mometaosone or budesonide
          1589 BECLOMETHASONE
           518 FLUNISOLIDE
             1 FLUNISOLIDES
           518 FLUNISOLIDE
                 (FLUNISOLIDE OR FLUNISOLIDES)
          4064 TRIAMCINOLONE
             9 TRIAMCINOLONES
          4066 TRIAMCINOLONE
                 (TRIAMCINOLONE OR TRIAMCINOLONES)
          4973 ACETONIDE
           344 ACETONIDES
          5113 ACETONIDE
                 (ACETONIDE OR ACETONIDES)
          2331 TRIAMCINOLONE ACETONIDE
                 (TRIAMCINOLONE(W)ACETONIDE)
         33435 DEXAMETHASONE
            17 DEXAMETHASONES
         33436 DEXAMETHASONE
                 (DEXAMETHASONE OR DEXAMETHASONES)
            59 TIPREDANE
             1 CICLESONID
             0 REFLOPONIDE
             0 MOMETAOSONE
          1978 BUDESONIDE
L11      37485 BECLOMETHASONE OR FLUNISOLIDE OR TRIAMCINOLONE ACETONIDE OR
               DEXAMETHASONE OR TIPREDANE OR CICLESONID OR REFLOPONIDE OR MOMET
              AOSONE OR BUDESONIDE

=> s 73573-87-2
   REGlstRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.



L13         646 L12


=> s L13 and L11
```

```
L14         217 L13 AND L11

=> dup rem L14
PROCESSING COMPLETED FOR L14
L15          217 DUP REM L14 (0 DUPLICATES REMOVED)

=> s L14 and (AY<2002 or PY<2002 or PRY<2002)
       4142168 AY<2002
      21819042 PY<2002
       3591199 PRY<2002
L16         108 L14 AND (AY<2002 OR PY<2002 OR PRY<2002)

=> s water
       2377679 WATER
        256925 WATERS
L17    2433410 WATER
                 (WATER OR WATERS)

=> s L16 and L17
L18          14 L16 AND L17

=> s aqueous and L16
        171951 AQUEOUS
             1 AQUEOUSES
        171952 AQUEOUS
                 (AQUEOUS OR AQUEOUSES)
       1052024 AQ
           156 AQS
       1052116 AQ
                 (AQ OR AQS)
       1086511 AQUEOUS
                 (AQUEOUS OR AQ)
L19           7 AQUEOUS AND L16

=> d L18 1-14 ibib abs

L18  ANSWER 1 OF 14  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:1311702  CAPLUS
DOCUMENT NUMBER:          144:57525
TITLE:                    Coated vaginal devices for vaginal delivery of
                          therapeutically effective and/or health-promoting
                          agents
INVENTOR(S):              Wilson, Michelle; Desai, Kishorkumar J.; Pauletti,
                          Giovanni M.; Antoon, Mitchell K.; Clendening, Chris E.
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S.
                          Ser. No. 126,863
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   11
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
     US 2005276836        A1    20051215    US 2005-180076          20050712 <--
     US 6197327           B1    20010306    US 1998-79897           19980515 <--
     US 6086909           A     20000711    US 1999-249963          19990212 <--
     US 6572874           B1    20030603    US 2000-626025          20000727 <--
     NZ 508130            A     20020301    NZ 2000-508130          20001113 <--
     AU 765269            B2    20030911    AU 2001-54192           20010703 <--
     US 2003049302        A1    20030313    US 2002-226667          20020821 <--
     US 6982091           B2    20060103
     US 2004005345        A1    20040108    US 2003-349029          20030122 <--
```

US 6905701	B2	20050614			
US 2004043071	A1	20040304	US 2003-600849		20030620
US 2005249774	A1	20051110	US 2005-126863		20050510 <--
US 2006002966	A1	20060105	US 2005-208209		20050818 <--
PRIORITY APPLN. INFO.:			US 1997-49325P	P	19970611 <--
			US 1998-79897	A2	19980515 <--
			US 1999-249963	A2	19990212 <--
			US 2000-626025	A2	20000727 <--
			US 2002-226667	A2	20020821
			US 2003-349029	A2	20030122
			US 2003-600849	A2	20030620
			US 2004-587454P	P	20040712
			US 2005-126863	A2	20050510
			AU 1998-76976	A3	19980610 <--
			NZ 1998-502120	A1	19980610 <--
			US 1999-146218P	P	19990728 <--
			US 2001-315877P	P	20010829 <--
			US 2002-390748P	P	20020621

AB Disclosed is a vaginal device for delivering therapeutical and/or health-promoting agents. The vaginal device partly or completely coated by, covered by or combined with a coating or covering comprising a film, foam, strip, cap, cup or particles. The coating of the device comprises a mucoadhesive composition comprising a therapeutical and/or health-promoting agent. For example, sumatriptan vaginal suppository were prepared from Suppocire AS2X, hydroxypropyl Me cellulose as a mucoadhesive agent, and Transcutol as a permeation enhancer.

L18 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:376128 CAPLUS
DOCUMENT NUMBER: 138:374176
TITLE: **Water** soluble or nonwater soluble nanoparticulates generation directly in suspension or dispersion media
INVENTOR(S): Mohsen, Nahed M.; Armer, Thomas A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2003091513	A1	20030515	US 2002-264030		20021003 <--
PRIORITY APPLN. INFO.:			US 2001-326442P	P	20011003 <--

AB A method for preparing a formulation containing nanoparticles of a compound is described. The method includes forming the compound into nanoparticles and then delivering the nanoparticles directly to a collection media. The collection media is a desired component of the formulation. The nanomedicaments are fabricated using supercrit fluid processes. An example formulation contained **budesonide**, Tyloxapol, benzalkonium chloride, and citrate buffer.

L18 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:376127 CAPLUS
DOCUMENT NUMBER: 138:390904
TITLE: **Water** stabilized medicinal aerosol formulation
INVENTOR(S): Adjei, Akwete; Cutie, Anthony J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U. S. Ser. No. 619,183, abandoned.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003091512	A1	20030515	US 2002-234825	20020903 <--
US 6261539	B1	20010717	US 1998-209228	19981210 <--
CA 2497171	AA	20040318	CA 2003-2497171	20030903
WO 2004022035	A1	20040318	WO 2003-US27245	20030903
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003272251	A1	20040329	AU 2003-272251	20030903
EP 1569617	A1	20050907	EP 2003-754425	20030903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006502160	T2	20060119	JP 2004-534386	20030903

PRIORITY APPLN. INFO.:
US 1998-209228 A2 19981210 <--
US 2000-619183 B2 20000719 <--
US 2002-234825 A 20020903
WO 2003-US27245 W 20030903

AB This invention relates to a medicinal aerosol suspension formulation and more particularly, to a medicinal aerosol formulation containing a particulate drug or a combination of at least two particulate drugs, a propellant and a stabilizing agent comprising a **water** addition

L18 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:813911 CAPLUS
DOCUMENT NUMBER: 137:316082
TITLE: Formoterol/steroid bronchodilating compositions and methods of use thereof
INVENTOR(S): Banerjee, Partha S.; Chaudry, Imitiaz A.
PATENT ASSIGNEE(S): Dey LP, USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083113	A2	20021024	WO 2002-US6252	20020301 <--
WO 2002083113	A3	20030320		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003055026	A1	20030320	US 2001-887496	20010622 <--

CA 2444535	AA	20021024	CA 2002-2444535		20020301 <--
EP 1385494	A2	20040204	EP 2002-719098		20020301 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2005512944	T2	20050512	JP 2002-580917		20020301 <--
US 2002183293	A1	20021205	US 2002-145978		20020513 <--
PRIORITY APPLN. INFO.:			US 2001-284607P	P	20010417 <--
			US 2001-887496	A1	20010622 <--
			WO 2002-US6252	W	20020301

AB Bronchodilating compns. intended for administration as a nebulized aerosol are provided. In certain embodiments, the compns. contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compns. provided herein are also provided. For example, a solution was prepared containing Formoterol fumarate dihydrate 85 μg/mL, **budesonide** 125 μg/mL, vitamin E TPGS 10 μg/mL, Polyethylene glycol 10 μg/mL, citrate buffer 50mM, sodium chloride 7.5 mg/mL, and **water** as needed.

L18 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:574906 CAPLUS
DOCUMENT NUMBER: 137:129896
TITLE: Process for preparing particles of a protein or polypeptide
INVENTOR(S): Sundholm, Goran Eric; Demirbuker, Mustafa; Moshashaee, Saeed
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002058674	A2	20020801	WO 2002-GB261		20020121 <--
WO 2002058674	A3	20021121			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2433838	AA	20020801	CA 2002-2433838		20020121 <--
EP 1357901	A2	20031105	EP 2002-715546		20020121 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2002006439	A	20031230	BR 2002-6439		20020121 <--
JP 2004521891	T2	20040722	JP 2002-559008		20020122 <--
NZ 526942	A	20050429	NZ 2002-526942		20020122 <--
ZA 2003004953	A	20040825	ZA 2003-4953		20030625 <--
US 2004058007	A1	20040325	US 2003-250868		20030708 <--
NO 2003003241	A	20030717	NO 2003-3241		20030717 <--
PRIORITY APPLN. INFO.:			GB 2001-2075	A	20010126 <--
			WO 2002-GB261	W	20020121

AB A process for preparing particles of a substance, such as a protein or polypeptide, comprising: (a) preparing a first liquid comprising **water**, the substance and a modulator, wherein the modulator has a solubility in **water** which decreases with increasing temperature; and (b) contacting

the first liquid with a second liquid comprising a fluid gas and an organic solvent using an anti-solvent fluid gas technique under conditions of temperature and pressure which result in the precipitation of particles comprising the substance, wherein the temperature of the first liquid is at or above the cloud point temperature of the first liquid when the first liquid contacts the second liquid Also claimed are particles obtained according to the process and compns. containing the particles. Lysozyme was dissolved in a tri-Et citrate solution, mixed with CO2 modified with ethanol through a coaxial nozzle, and processed in a SEDS particle formation chamber.

L18 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:555336 CAPLUS
DOCUMENT NUMBER: 137:114526
TITLE: A method for the preparation of nanoparticles
INVENTOR(S): Watanabe, Wiwik; Kauppinen, Esko; Ahonen, Petri; Brown, David; Muttonen, Esa
PATENT ASSIGNEE(S): Orion Corporation, Finland
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002056866	A1	20020725	WO 2002-FI42	20020118 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1351666	A1	20031015	EP 2002-710900	20020118 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004520157	T2	20040708	JP 2002-557374	20020118 <--
US 2004091542	A1	20040513	US 2003-466365	20031211 <--
PRIORITY APPLN. INFO.:			FI 2001-115 A	20010118 <--
			WO 2002-FI42 W	20020118

AB The invention relates to free nano-sized particles of active agents e.g. therapeutic, cosmetic or diagnostic agents, and to a method for the preparation of such particles. The method comprises providing a liquid feed stock comprising an active agent or combination of two or more active agents, atomizing the liquid feed stock, suspending the droplets in a carrier gas, and passing the carrier gas and droplets through a heated tube flow reactor under predetd. residence time and temperature history, and collecting the particles produced. Nano-sized crystalline spherical uncharged particles with narrow aerodynamic particle size distribution and rough surfaces, are obtained. The particles show improved dissoln. rate in-vitro and bioavailability in-vivo, dispersibility and stability. Nanosized **beclomethasone** dipropionate particles were prepared
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:487374 CAPLUS
DOCUMENT NUMBER: 137:52399

TITLE: Pharmaceutical aerosol formulations containing alkyl polyglycoside
INVENTOR(S): Buckton, Graham; Columbano, Angela; Grosvenor, Martin; Wikeley, Philip
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049616	A1	20020627	WO 2001-SE2853	20011219 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002016576	A5	20020701	AU 2002-16576	20011219 <--
EP 1345591	A1	20030924	EP 2001-271213	20011219 <--
EP 1345591	B1	20050302		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004516261	T2	20040603	JP 2002-550958	20011219 <--
AT 289803	E	20050315	AT 2001-271213	20011219 <--
US 2004082520	A1	20040429	US 2003-451162	20031125 <--

PRIORITY APPLN. INFO.:	SE 2000-4750	A	20001219 <--
	WO 2001-SE2853	W	20011219 <--

OTHER SOURCE(S): MARPAT 137:52399

AB The invention relates to a pharmaceutical aerosol formulation comprising a surfactant that is an alkyl polyglycoside (the average degree of polymerization of 1-4) for the administration of a drug for inhalation. Propellant HFA-134a was was dispensed chilled (at -55°) into a 400-mL can. A valve was then crimped onto the can and the propellant allowed to return to ambient temperature **Beclomethasone** dipropionate was weighed into a 30-mL glass vial and 20 mL of surfactant (alkyl polyglycoside at 0.8 g/L) solution in **water**. The resultant suspension was incubated at 25° for 3 h hours, to allow adsorption of the surfactant to the surface of the drug, and to give a drug-surfactant ratio of 10 mg surfactant/g drug. The suspension was centrifuged and the particles of drug-surfactant were separated from the supernatant and dried in an oven at 50° for 24 h. This was mixed with the propellant, and the final composition contained **beclomethasone** dipropionate and glycoside 0.2% and HFA-134a to 100%.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:122837 CAPLUS
DOCUMENT NUMBER: 136:189346
TITLE: Medical electropowders for inhalers
INVENTOR(S): Nilsson, Thomas; Nilsson, Lars-Gunnar
PATENT ASSIGNEE(S): Microdrug A.-G., Switz.
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002011803	A1	20020214	WO 2001-SE1682	20010727 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
SE 2000002822	A	20020129	SE 2000-2822	20000804 <--
SE 516555	C2	20020129		
US 6696090	B1	20040224	US 2000-636548	20000811 <--
CA 2417225	AA	20020214	CA 2001-2417225	20010727 <--
AU 2001082743	A5	20020218	AU 2001-82743	20010727 <--
EP 1309369	A1	20030514	EP 2001-961481	20010727 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012903	A	20030701	BR 2001-12903	20010727 <--
JP 2004505685	T2	20040226	JP 2002-517135	20010727 <--

PRIORITY APPLN. INFO.: SE 2000-2822 A 20000804 <--
WO 2001-SE1682 W 20010727 <--

AB A method and a process are disclosed for preparation of medical electro-powders. The electro-powder results from prepns. of chemical and biol. substances to form electro-powders suitable for electrostatic charging and dosing for functionality in a dry powder inhaler device. The electro-powder resulting from the method and process forms an active powder substance or a dry powder medical formulation with a fine particle fraction representing of the order 50 or more of the content having a size ranging between 0,5-5 μm and provides electrostatic properties with an absolute specific charge per mass after charging of the order 0.1x10-6 to 25x10-6 C/g and presenting a charge decay rate constant Q50 > 0.1 s with a tap d. of less than 0.9 g/mL and a **water** activity aw of less than O.5. In the processing the active substance is a generally pharmacol. active chemical or biol. substance, for instance a polypeptide or any other corresponding substance selected alone or mixed or blended together with one or more excipients being a compound to improve electrostatic properties of the medical dry powder substance or dry powder medical formulation. Further the electro-powder may even be formed as a micro-encapsulation by coating micronized powder with the excipient in such a way that the active substance is capsulated whereby the powder electrostatic properties mainly comes from the excipient. Terbutaline sulfate, used for asthma treatment, was micronized and analyzed for particle size.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:89782 CAPLUS
DOCUMENT NUMBER: 136:139841
TITLE: A medicinal aerosol formulation containing a particulate drug
INVENTOR(S): Adjei, Akwete L.; Cutie, Anthony J.
PATENT ASSIGNEE(S): Aeropharm Technology, Inc., USA
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002007672	A2	20020131	WO 2000-US42625	20001207 <--
WO 2002007672	A3	20020627		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001047123	A5	20020205	AU 2001-47123		20001207 <--
PRIORITY APPLN. INFO.:			US 2000-619183	A	20000719 <--
			WO 2000-US42625	W	20001207 <--

AB This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a particulate drug, or combination of at least two particulate drugs a propellant and a stabilizing agent comprising a **water** addition (no data).

L18 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:863509 CAPLUS
DOCUMENT NUMBER: 136:15232
TITLE: Methods for treating immunomediated inflammatory disorders and changing skin pigmentation
INVENTOR(S): Costanzo, Michael J.
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE: U.S., 52 pp., Cont.-in-part of U.S. Ser. No. 110,409.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6323219	B1	20011127	US 1999-238882	19990127 <--
AU 2002305718	A1	20031212	AU 2002-305718	20020524
EP 1507509	A1	20050223	EP 2002-734558	20020524

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:	US 1998-80441P	P	19980402 <--
	US 1998-110409	A2	19980706 <--
	WO 2002-US16713	A	20020524

OTHER SOURCE(S): MARPAT 136:15232

AB Methods and compns. are provided for bringing about changes in skin pigmentation and for treating inflammatory disorders. More particularly, the invention provides compds. which affect melanogenesis and can be used as depigmenting agents or as agents for darkening skin utilizing the protease-activated receptor 2 (PAR-2) pathway and compds. for the prevention and treatment of immunomediated inflammatory diseases, particularly those associated with the respiratory tract, e.g. asthma and allergic rhinitis.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:401693 CAPLUS
DOCUMENT NUMBER: 133:34456
TITLE: A medicinal aerosol formulation

INVENTOR(S): Adjei, Akwete; Cutie, Anthony J.
PATENT ASSIGNEE(S): Aeropharm Technology Incorporated, USA
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033892	A1	20000615	WO 1999-US28644	19991203 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6261539	B1	20010717	US 1998-209228	19981210 <--
CA 2353959	AA	20000615	CA 1999-2353959	19991203 <--
EP 1135173	A1	20010926	EP 1999-965104	19991203 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 749636	B2	20020627	AU 2000-31089	19991203 <--
JP 2003521459	T2	20030715	JP 2000-586382	19991203 <--

PRIORITY APPLN. INFO.: US 1998-209228 A 19981210 <--
WO 1999-US28644 W 19991203 <--

AB This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a particulate drug, a propellant and a stabilizing agent comprising a **water** addition Generally the formulations can be prepared by combining (1) the drug, e.g. **triamcinolone acetonide**, in an amount sufficient to provide a plurality of therapeutically EDs, (2) the **water** addition in an amount effective to stabilize each of the formulations, (3) the propellant in an amount sufficient to propel a plurality of doses from an aerosol canister, and (4) any further optional components, e.g. ethanol as a cosolvent and dispersing the components.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:351357 CAPLUS
DOCUMENT NUMBER: 133:9107
TITLE: Dry powder for inhalation
INVENTOR(S): Keller, Manfred; Mueller-Walz, Rudi
PATENT ASSIGNEE(S): Skyepharma A.-G., Switz.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000028979	A1	20000525	WO 1999-CH528	19991110 <--
W: AU, CA, CN, CZ, HU, IN, JP, NO, NZ, PL, RO, RU, SK, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2347856	AA	20000525	CA 1999-2347856	19991110 <--
AU 9964578	A1	20000605	AU 1999-64578	19991110 <--
AU 756852	B2	20030123		

EP 1131059	A1	20010912	EP 1999-952212	19991110 <--
EP 1131059	B1	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO				
JP 2002529498	T2	20020910	JP 2000-582027	19991110 <--
NZ 511527	A	20021025	NZ 1999-511527	19991110 <--
EP 1283036	A1	20030212	EP 2002-25796	19991110 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AT 233550	E	20030315	AT 1999-952212	19991110 <--
PT 1131059	T	20030731	PT 1999-952212	19991110 <--
ES 2192866	T3	20031016	ES 1999-952212	19991110 <--
RU 2221552	C2	20040120	RU 2001-116074	19991110 <--
SK 284889	B6	20060202	SK 2001-632	19991110 <--
ZA 2001003627	A	20010509	ZA 2001-3627	20010504 <--
NO 2001002346	A	20010626	NO 2001-2346	20010511 <--
US 6645466	B1	20031111	US 2001-831011	20010809 <--
US 2004202616	A1	20041014	US 2003-628965	20030728 <--
PRIORITY APPLN. INFO.:			CH 1998-2286 A	19981113 <--
			EP 1999-952212 A3	19991110 <--
			WO 1999-CH528 W	19991110 <--
			US 2001-831011 A1	20010809 <--

AB The moisture resistance of dry powder formulations for inhalation, which contain a pharmaceutically inert carrier of noninhalable particle size and a finely divided pharmaceutical substance of inhalable particle size, is improved and the storage stability of the formulations is increased by adding Mg stearate to minimize the deleterious effect of moisture on fine particle dose and fine particle fraction even under relatively extreme temperature and humidity conditions. Thus, 198.46 g lactose-H2O (particle size 100% <200 μm, 50% <125 μm, 10% <75 μm) was mixed with 1 g sieved Mg stearate, then with 0.54 g formoterol fumarate-2H2O, and loaded into a multidose dry powder inhaler.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:96087 CAPLUS
DOCUMENT NUMBER: 132:141964
TITLE: Two-piece capsule for pharmaceutical preparations for dry powder inhalers
INVENTOR(S): Hochrainer, Dieter; Eckert, Josef
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: Ger. Offen., 10 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19835346	A1	20000210	DE 1998-19835346	19980805 <--
CA 2338323	AA	20000217	CA 1999-2338323	19990803 <--
WO 2000007572	A2	20000217	WO 1999-EP5614	19990803 <--
WO 2000007572	A3	20000511		
W: AU, BG, BR, CA, CN, CZ, EE, HU, ID, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9957304	A1	20000228	AU 1999-57304	19990803 <--
AU 763266	B2	20030717		
BR 9912748	A	20010515	BR 1999-12748	19990803 <--
EP 1100474	A2	20010523	EP 1999-944325	19990803 <--

EP 1100474	B1	20020717			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
TR 200100355	T2	20010621	TR 2001-200100355		19990803 <--
EE 200100073	A	20020617	EE 2001-73		19990803 <--
EE 4451	B1	20050415			
JP 2002522378	T2	20020723	JP 2000-563258		19990803 <--
AT 220542	E	20020815	AT 1999-944325		19990803 <--
PT 1100474	T	20021231	PT 1999-944325		19990803 <--
ES 2180325	T3	20030201	ES 1999-944325		19990803 <--
SK 283568	B6	20030911	SK 2001-169		19990803 <--
NZ 509977	A	20031128	NZ 1999-509977		19990803 <--
TW 221420	B1	20041001	TW 1999-88113240		19990803 <--
BG 105189	A	20010731	BG 2001-105189		20010126 <--
BG 64115	B1	20040130			
ZA 2001000796	A	20020529	ZA 2001-796		20010129 <--
NO 2001000535	A	20010131	NO 2001-535		20010131 <--
US 2001008637	A1	20010719	US 2001-800647		20010307 <--
HK 1037975	A1	20041210	HK 2001-108874		20011219 <--
US 2004131668	A1	20040708	US 2003-740225		20031218 <--
PRIORITY APPLN. INFO.:			DE 1998-19835346	A	19980805 <--
			US 1998-113214P	P	19981222 <--
			US 1999-365912	A1	19990803 <--
			WO 1999-EP5614	W	19990803 <--
			US 2001-800647	A1	20010307 <--

AB Capsules for pharmaceutical prepns. for use in dry powder inhalers with increased drug safety consist of **water**-insol., hydrophobic plastics which do not substantially affect the pharmaceutical quality of the contents, but improve their useful life and/or the geog. range of their use (especially with regard to humidity). The capsules have a Shore hardness of 65-73, such that during opening or puncture of the capsule, no capsule fragments are produced which could be inhaled, and that the capsule cannot spontaneously reseal after opening or puncture. They can withstand a force of ≤15 N in all directions during manufacture, filling, packing, and transport. The capsules have a permeability for **water** vapor of <1.3 + 10-14 kg/(m2 s Pa).

L18 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	1995:528673 CAPLUS
DOCUMENT NUMBER:	122:274076
TITLE:	Process for conditioning substances
INVENTOR(S):	Trofast, Eva Ann-Christin; Briggner, Lars-Erik
PATENT ASSIGNEE(S):	Astra Aktiebolag, Swed.
SOURCE:	PCT Int. Appl., 20 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9505805	A1	19950302	WO 1994-SE780	19940825 <--
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9405675	A	19960429	ZA 1994-5675	19940729 <--
TW 427916	B	20010401	TW 1994-83107152	19940804 <--
IL 110698	A1	20021110	IL 1994-110698	19940818 <--
CA 2170394	AA	19950302	CA 1994-2170394	19940825 <--
CA 2170394	C	20041012		

AU 9476264	A1	19950321	AU 1994-76264	19940825 <--
AU 681186	B2	19970821		
BR 9407320	A	19960416	BR 1994-7320	19940825 <--
EP 717616	A1	19960626	EP 1994-926421	19940825 <--
EP 717616	B1	20010321		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1133004	A	19961009	CN 1994-193793	19940825 <--
CN 1049333	B	20000216		
HU 74000	A2	19961028	HU 1996-447	19940825 <--
HU 217770	B	20000428		
JP 09501930	T2	19970225	JP 1994-507516	19940825 <--
JP 2978247	B2	19991115		
PL 176749	B1	19990730	PL 1994-313142	19940825 <--
RU 2148992	C1	20000520	RU 1996-105935	19940825 <--
AT 199828	E	20010415	AT 1994-926421	19940825 <--
ES 2156158	T3	20010616	ES 1994-926421	19940825 <--
PT 717616	T	20010830	PT 1994-926421	19940825 <--
CZ 289018	B6	20011017	CZ 1996-544	19940825 <--
SK 283146	B6	20030304	SK 1996-234	19940825 <--
US 5709884	A	19980120	US 1995-379471	19950130 <--
NO 9600744	A	19960223	NO 1996-744	19960223 <--
NO 312433	B1	20020513		
FI 9600869	A	19960226	FI 1996-869	19960226 <--
CN 1195523	A	19981014	CN 1997-123049	19971126 <--
CN 1090019	B	20020904		
HK 1016493	A1	20030425	HK 1999-101600	19990414 <--
GR 3036106	T3	20010928	GR 2001-400955	20010621 <--
PRIORITY APPLN. INFO.:			SE 1993-2777 A	19930827 <--
			WO 1994-SE780 W	19940825 <--

AB The present invention relates to a process for providing a stable crystalline form to a fine-grained substance or a substance mixture, which can be produced, stored and used while maintaining the aerodynamic properties required for inhalation of such a substance or a substance mixture, by a) in case of a substance mixture, preparing a homogeneous mixture of the substances; b) micronizing, direct precipitating or diminishing by any conventional method the substance or substance mixture into a particle size required for inhalation, the particle size being less than 10 μm; c) optionally preparing a homogeneous mixture of the desired substances when each substance has been introduced from stage b) as sep. fine-grained particles; d) conditioning said substance or substance mixture by treatment with a **water** containing vapor phase in a controlled fashion; and e) drying.

=> d L19 1-7 ibib abs

L19 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2003:376641 CAPLUS
DOCUMENT NUMBER:	138:385438
TITLE:	Preparation of pyridazinylmethanoylphenylhydrazonomalo nitriles as phosphodiesterase IV inhibitors.
INVENTOR(S):	Eggenweiler, Hans-Michael; Wolf, Michael; Beier, Norbert; Schelling, Pierre; Ehring, Thomas
PATENT ASSIGNEE(S):	Merck Patent Gmbh, Germany
SOURCE:	PCT Int. Appl., 114 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003039548	A1	20030515	WO 2002-EP11351	20021010 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2465746	AA	20030515	CA 2002-2465746		20021010 <--
EP 1441730	A1	20040804	EP 2002-802625		20021010 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
BR 2002013683	A	20041026	BR 2002-13683		20021010 <--
CN 1585641	A	20050223	CN 2002-822216		20021010 <--
JP 2005511595	T2	20050428	JP 2003-541839		20021010 <--
US 2004261190	A1	20041230	US 2004-494631		20040504 <--
PRIORITY APPLN. INFO.:			EP 2001-125455	A	20011105 <--
			WO 2002-EP11351	W	20021010

OTHER SOURCE(S): MARPAT 138:385438
GI



I

AB Title compds. [I; R1, R2 = H, OH, OR5, SR5, SOR5, SO2R5, X; R1R2 = OCH2O, OCH2CH2O; R3, R31 = H, R5, OH, OR5, NH2, NHR5, NHCOR5, X, CO2H, CO2R5, CONH2, etc.; R4 = cyano, tetrazolyl; R5 = (fluoro-substituted) A, cycloalkyl, (CH2)nAr; A = (fluoro- and/or chloro-substituted) alkyl, alkenyl; Ar = Ph; n = 0-2; X = F, Cl, Br, iodo], were prepared Thus, [3-(3,4-diethoxyphenyl)-5,6-dihydro-4H-pyridazine-1-yl]-(3-aminophenyl)methanone (preparation given) was stirred with NaNO2 in **aq** . HCl for 1 h at -2° to 0°; malononitrile in H2O was added followed by stirring for 2 h to give a residue which was treated with KOH in MeOH to give 2-[[3-[1-[3-(3,4-diethoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]methanoyl]phenyl]hydrazono]malononitrile K salt. I were said to give a marked reduction of T cell proliferation. I are claimed for treatment of osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases, AIDS, etc.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2003:257320 CAPLUS
DOCUMENT NUMBER:	138:260488
TITLE:	Method for the production of sterile liquid preparations for inhalation
INVENTOR(S):	Keller, Manfred; Lintz, Frank
PATENT ASSIGNEE(S):	Pari Gmbh, Germany
SOURCE:	Ger. Offen., 14 pp. CODEN: GWXXBX
DOCUMENT TYPE:	Patent
LANGUAGE:	German

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10145361	A1	20030403	DE 2001-10145361	20010914 <--
EP 1417958	A1	20040512	EP 2002-25006	20021108 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CA 2475577	AA	20040521	CA 2003-2475577	20031028
WO 2004041253	A1	20040521	WO 2003-EP11949	20031028
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003279326	A1	20040607	AU 2003-279326	20031028
EP 1558217	A1	20050803	EP 2003-772269	20031028
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006057073	A1	20060316	US 2004-517910	20041208

PRIORITY APPLN. INFO.:
DE 2001-10145361 A 20010914 <--
EP 2002-25006 A 20021108
WO 2003-EP11949 W 20031028

AB The invention concerns the production of sterile **aq**. inhalation aerosols containing slightly soluble drugs by (a) preparing an **aq**. suspension containing drug particles larger than 1 μm and a dissolved surfactant; (b) reduction of the particle size by high pressure homogenization or collision jet grinding to obtain particles less than 1 μm; (c) heat treatment of the suspension for sterilization, the final average particle size is less than 2 μm. The inhalants are formulated for pulmonary and nasal use. Suspensions can be nebulized by aerosol nozzles, ultrasound, vibrating membranes with defined pore sizes or electrohydrodynamically.

L19 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:671829 CAPLUS
DOCUMENT NUMBER: 137:206550
TITLE: Inhalatory compositions of formoterol
INVENTOR(S): Gagnoni, Alessandro; Meoli, Andrea; Vanossi, Sereno
PATENT ASSIGNEE(S): Chemo Healthcare S.A., Switz.
SOURCE: Eur. Pat. Appl., 7 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1236467	A1	20020904	EP 2002-4635	20020228 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2374257	AA	20020902	CA 2002-2374257	20020301 <--
US 2002155068	A1	20021024	US 2002-86868	20020304 <--
US 6719994	B2	20040413		

PRIORITY APPLN. INFO.:
IT 2001-MI428 A 20010302 <--

AB Inhalatory pharmaceutical compns. containing formoterol as active ingredient, comprises a vial containing a sterile liquid vehicle suitable for inhalation, a reservoir chamber cap containing a powder mixture consisting of Formoterol or a

related salt in micronized form and one or more excipients, soluble in the vehicle and suitable for respiratory use. The composition comprises a further active ingredient, i.e., **budesonide**, fluticasone, **flunisolide**, mometasone or ipratropium bromide.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:594842 CAPLUS
DOCUMENT NUMBER: 137:154859
TITLE: Preparation of carbamoyl-substituted pyridinyl aryl ether derivatives as inhibitors of phosphodiesterase IV isozymes
INVENTOR(S): Chambers, Robert James; Magee, Thomas Victor; Marfat, Anthony
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 285 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002060896	A1	20020808	WO 2001-IB2726		20011224 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2436544	AA	20020808	CA 2001-2436544		20011224 <--
EE 200300361	A	20031215	EE 2003-361		20011224 <--
EP 1373258	A1	20040102	EP 2001-273558		20011224 <--
EP 1373258	B1	20050928			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001016845	A	20040225	BR 2001-16845		20011224 <--
JP 2004518689	T2	20040624	JP 2002-561464		20011224 <--
CN 1527830	A	20040908	CN 2001-823098		20011224 <--
NZ 526531	A	20050225	NZ 2001-526531		20011224 <--
AT 305467	E	20051015	AT 2001-273558		20011224 <--
US 2003027845	A1	20030206	US 2002-66503		20020131 <--
US 6828333	B2	20041207			
ZA 2003004893	A	20040624	ZA 2003-4893		20030624 <--
BG 107960	A	20041029	BG 2003-107960		20030701 <--
NO 2003003399	A	20030925	NO 2003-3399		20030730 <--
US 2005049258	A1	20050303	US 2004-918820		20040813 <--
PRIORITY APPLN. INFO.:			US 2001-265304P	P	20010131 <--
			WO 2001-IB2726	W	20011224 <--
			US 2002-66503	A3	20020131

OTHER SOURCE(S): MARPAT 137:154859
GI



I



II

AB Title compds. compds. I [wherein p = 0-1, provided that when p = 0, n = 2; m = 1-3; n = 1-2; W1 and W2 = independently O, S(O)0-2, or NR3; Y = =C(R1a) or N(O)0-1; R1a = H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, fluoroalkoxy, OR16, or (un)substituted carbamoyl; RA and RB = independently H, F, CF3, or (un)substituted (cyclo)alkyl, Ph, or benzyl; or CRARB = spiro moiety; RC and RD = the same as RA and RB except that one of them must be H; R1 and R2 = independently H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, OR16, or (un)substituted carbamoyl; R3 = H, alkyl, Ph, benzyl, or OR16; R4, R5 and R6 = independently H, F. Cl, alkynyl, R16, OR16, SO0-2R16, COR16, CO2R16, OCOR16, CN, NO2, (un)substituted carbamoyl(oxy), ureido, carboximidoyl, aryl, heterocyclyl, etc.; or R5 and R6 taken together with the atoms to which they are attached = (hetero)cyclyl; J1 and J2 = independently (un)substituted, (un)saturated monocyclic or fused polycyclic ring; D = (un)substituted carboxy, carbamoyl, acyl, hydroxy(alkyl), cyano(alkyl), etc.; R16 = H or (un)substituted (cyclo)alkyl, alkenyl, Ph, benzyl, or pyridyl] were prepared as inhibitors of PDE4 (no data). For example, 2-(benzo[1,3]dioxol-5-yloxy)nicotinic acid was coupled with (4-aminomethyl-3-fluorophenoxy)acetic acid Me ester in the presence of 1-hydroxybenzotriazole•H2O and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide•HCl in DMF/CH2Cl2 to give the pyridinecarboxamide II (R = Me) in 38% yield. Saponification using **aq.** LiOH in THF and MeOH afforded the desired acid II (R = OH) in 21% yield. I are useful in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease (no data). In addition, I may be used in combination therapy with a wide variety of other therapeutic agents.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:591707 CAPLUS

DOCUMENT NUMBER: 137:140509

TITLE: Preparation of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isozymes

INVENTOR(S): Chambers, Robert J.; Magee, Thomas V.; Marfat, Anthony

PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 180 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
EP 1229034	A1	20020807	EP 2002-250202		20020111	<--
EP 1229034	B1	20050413				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
AT 293109	E	20050415	AT 2002-250202		20020111	<--
ES 2239203	T3	20050916	ES 2002-2250202		20020111	<--
CA 2369462	AA	20020731	CA 2002-2369462		20020129	<--
US 2002111495	A1	20020815	US 2002-62811		20020131	<--
BR 2002000250	A	20021008	BR 2002-250		20020131	<--
US 2004171798	A1	20040902	US 2004-781062		20040217	<--
PRIORITY APPLN. INFO.:			US 2001-265240P	P	20010131	<--
			US 1997-43403P	P	19970404	<--
			US 1998-105120P	P	19981021	<--
			US 2002-62811	B1	20020131	

OTHER SOURCE(S): MARPAT 137:140509
GI



I

AB Title compds. [I; p, q = 0, 1; m = 0-2; n = 1, 2; A = CO2R7, CONR9CO2R7, CONR7R9, OP(O)(OH)2, SO3H, acylsulfonamido, etc.; W = O, S, SO, SO2, NR3; Y = N, NO, CR11; R1, R2 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, etc.; R3 = H, alkyl, Ph, PhCH2, etc.; R4-R6 = H, F, Cl, alkynyl, cyano, NO2, etc.; R7 = H, (substituted) alkyl, alkenyl, alkynyl; R9 = H, alkyl, cycloalkyl, Ph, PhCH2, pyridyl, etc.; R11 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, fluoroalkoxy, etc.; Ra, Rb = H, F, CF3, alkyl, (substituted) cycloalkyl, Ph, PhCH2; B1, B2 = 3-7 membered (hetero)cyclyl, 7-12 membered poly(hetero)cyclyl; pairs of variables may form rings; with provisos], were prepared (no data). Thus, Me 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionate was suspended in Me3COH. **Aq**. NaOH was added to the suspension, and the reaction mixture was refluxed 1 h to give 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionic acid.
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:152458 CAPLUS
DOCUMENT NUMBER: 134:183526
TITLE: Method to produce powders for pulmonary or nasal administration
INVENTOR(S): Woolfe, Austen John; Zeng, Xian Ming; Langford, Alan
PATENT ASSIGNEE(S): Norton Healthcare Ltd., UK
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001013885	A1	20010301	WO 2000-GB3230	20000821 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2382216	AA	20010301	CA 2000-2382216	20000821 <--
JP 2003526629	T2	20030909	JP 2001-518024	20000821 <--
PRIORITY APPLN. INFO.:			US 1999-150095P P	19990820 <--
			WO 2000-GB3230 W	20000821 <--

AB A pharmaceutical formulation comprises a mixture of two or more drugs optionally together with one or more excipients, the mixture being formed by the steps of: co-crystallization or co-precipitation of the drugs followed by micronization or milling to produce a uniform powder having a particle size and other properties suitable for formulation for pulmonary or nasal administration. An **aq**. solution of 5% salbutamol sulfate:ipratropium bromide (10:1) mixture was prepared and was spray dried. The diameter of particles was less than 3 μm.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1989:13580 CAPLUS
DOCUMENT NUMBER: 110:13580
TITLE: Formation of dry liposomes and their administration as aerosols
INVENTOR(S): Axelsson, Bengt Ingemar; Bystroem, Ulla Katarina; Dahlbaeck, Carl Magnus Olof; Kaellstroem, Leif Arne; Nilsson, Per Gunnar; Trofast, Jan William
PATENT ASSIGNEE(S): Draco AB, Swed.
SOURCE: Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 260241	A1	19880316	EP 1987-850273	19870908 <--
R: ES, GR				
ZA 8706641	A	19880427	ZA 1987-6641	19870904 <--
WO 8801862	A1	19880324	WO 1987-SE401	19870908 <--
W: AT, AU, BB, BG, BR, CH, DE, DK, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, RO, SD, SE, SU				
RW: AT, BE, BJ, CF, CG, CH, CM, DE, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
AU 8779133	A1	19880407	AU 1987-79133	19870908 <--
AU 603139	B2	19901108		
EP 282537	A1	19880921	EP 1987-906023	19870908 <--
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 01500668	T2	19890309	JP 1987-505390	19870908 <--
HU 47840	A2	19890428	HU 1987-4531	19870908 <--

HU 198835	B	19891228			
CA 1256798	A1	19890704	CA 1987-546527		19870910 <--
DK 8802473	A	19880506	DK 1988-2473		19880506 <--
FI 8802221	A	19880511	FI 1988-2221		19880511 <--
NO 8802077	A	19880511	NO 1988-2077		19880511 <--
PRIORITY APPLN. INFO.:			SE 1986-3812	A	19860912 <--
			WO 1987-SE401	A	19870908 <--

AB A system for administration of liposomes comprises a dry lipid-based solid material, which spontaneously forms or reconstitutes liposomes in an **aq**. medium, i.e., in vivo; the system also comprises a device for aerosolizing selected quantities of the dry liposomes. The system is especially used for inhalation of drugs e.g. antiasthmatics. Dipalmitoyl phosphatidylcholine 7.22 and flumethasone 21-palmitate 0.38 were dissolved in tert-BuOH 76 g under gentle heating; the solution was frozen and lyophilized and the resulting powder was dispersed in **aq**. 3.3% lactose (432 g solution). The liposome dispersion was spray-dried to give a powder suitable for inhalation therapy (<3 μm); 2.8 g of the lyophilized micronized powder was dispersed in 434 g chilled 65:35 propellant 114 - propellant 115 mixture, and the blend was filled into Al containers and sealed with 50 μL valves. Rats given Sephadex beads by intratracheal instillation were exposed to the aerosol daily for 3 consecutive days. Rats treated with different doses from the pressurized dose-aerosols showed a significant dose-response relationship; the high dose level (doses not given) inhibited the development of lung edema and the animals showed the same lung weight as normal untreated controls. Controls implanted with Sephadex and treated with placebo pressurized dose-aerosols lacking the spray-dried powder developed pulmonary edema.